Embodiments herein relate generally to high concentration VEGF receptor fusion protein containing formulations suitable for ocular administration. More particularly, embodiments herein provide liquid pharmaceutical formulations for intravitreal administration, where the formulations include more than 40 mg/ml VEGF receptor fusion protein, and show pharmaceutically acceptable potency, stability, viscosity and pH.
An official copy of the sequence listing is submitted concurrently with the specification electronically via EFS-Web as an ASCII formatted sequence listing with a file name of “10430US02-Sequence.txt”, a creation date of Jul. 23, 2021, and a size of 6,385 bytes. The sequence listing contained in this ASCII formatted document is part of the specification and is herein incorporated by reference in its entirety.
The development of a therapeutically useful liquid formulation requires a combination of ingredients, at differing amounts, to provide a functional and stable delivery vehicle for a drug of interest. This is particularly true where the drug is a protein, and furthermore, an antibody. Antibody formulations have long presented challenges to drug developers and manufacturers, as antibody activity and administration typically require a pharmaceutically acceptable potency, osmolality, protein stability, viscosity, and proper pH. These challenges are exacerbated when the antibody is at higher concentrations in the formulation, for example, beyond 20 to 40 mg/ml, the concentration of most pharmaceutically sold antibodies.
Higher concentration antibody formulations allow for shorter injection times, smaller injection volumes, lower frequency of antibody administration, and more efficient manufacturing and storage utility. However, as noted above, the higher the antibody or protein concentration, the more difficult it is to maintain the proper activity and delivery parameters for the formulation. In particular, high concentration antibody and protein formulations often contend with increased protein aggregation and viscosity, which results in lower overall antibody or protein potency, and lower manufacturing and poorer storage stability. Because of the issues related to high concentration protein or antibody formulations, few such pharmaceutically acceptable formulations have been developed. There is a need in the art for preparing high concentration, high stability, antibody and protein formulations that include the proper potency, stability, viscosity, osmolality and pH.
One such protein in need of high concentration formulations is the vascular endothelial growth factor (VEGF) receptor fusion protein. VEGF receptor fusion proteins are used to block VEGF function in a number of ophthalmic formulations, for example, EYLEA® (Regeneron Pharmaceuticals, Inc.). High concentration VEGF receptor fusion protein containing formulations could allow for shorter ocular injection times, smaller injection volumes, fewer possible injections per administration cycle, and more efficient manufacturing and storage.
The present invention is directed toward overcoming one or more of the problems discussed above.
Various embodiments described herein encompass high concentration protein containing formulations (e.g., which are suitable for intravitreal administration), and in particular, high concentration vascular endothelial growth factor (VEGF) receptor fusion protein containing formulations. High concentration VEGF receptor fusion protein containing formulations provide a number of therapeutic and economic benefits, including, pharmaceutically acceptable potency, long term manufacturing and storage stability, and a viscosity and pH compatible with ocular injection. High concentration VEGF receptor fusion protein containing formulations also allow for reduced ocular administration volumes, a benefit for avoiding undesired effects on the limited volume of the eye.
Embodiments herein provide formulations having a VEGF receptor fusion protein, a buffer, a thermal stabilizer, a viscosity reducing agent, and a surfactant. In other embodiments, the formulations do not include a viscosity reducing agent. Formulations of the present invention have a pH and viscosity suitable for injection, and in particular, for therapeutic ocular injection.
In an embodiment of the invention, a pharmaceutical formulation of the present invention is provided having a VEGF receptor fusion protein at a concentration of at least 41 mg/ml or a concentration that contains a single dose of VEGF receptor fusion protein (which is discussed herein) in less than about 100 μl, less than about 50 μl, about 50 μl, about 57 μl, about 60 μl, about 70 μl, or about 75 μl, a buffer, optionally a thermal stabilizer and/or a viscosity reducing agent, and a surfactant, where the formulation has a pH of from about 5.0 to about 6.8 (e.g., 5.8).
In an embodiment of the invention, the VEGF receptor fusion protein concentration is about 30 mg/ml, 60 mg/ml, 114 mg/ml, 120 mg/ml or 140 mg/ml.
In an embodiment of the invention, the surfactant can be a non-ionic surfactant (e.g., about 0.02% to about 0.1%; or about 0.03% (w/v)). In an embodiment of the invention, the surfactant is a non-ionic surfactant having a polyoxyethylene moiety, for example, polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188, polyethylene glycol 3350 or mixtures thereof.
In an embodiment of the invention, the buffer is a histidine-based buffer (e.g., 10 mM or 20 mM), such as histidine, histidine HCl or histidine acetate; a phosphate-based buffer, such as sodium phosphate (e.g., 10 mM); an acetate-based buffer, such as sodium acetate and acetic acid, or a citrate-based buffer, such as sodium citrate or citric acid. In an embodiment of the invention, if the buffer is phosphate buffer, the pH is from about 5.7 to about 8.0, about 5.8 to about 8.0, about 5.7 to about 7.0, about 5.8 to about 7.0, about 5.9 to about 7.0 or about 6.0 to about 7.0; if the buffer is histidine buffer, the pH is from about 5.5 to about 6.5; if the buffer is citrate buffer, the pH is from about 3.0 to about 6.2 or about 5.0 to about 6.0; and if the buffer is acetate buffer, the pH is from about 3.7 to about 5.6 or about 5.0 to about 6.0.
In an embodiment of the invention, the thermal stabilizer is a sugar, such as sucrose (e.g., about 2.5%, 5% or 8%, 10% or 20% (w/v), e.g., about 2-20%), mannitol, sorbitol, or trehalose; L-proline (e.g., about 2%, 3% or 4% (w/v)); glycine (e.g., about 50 mM), glycerol, taurine (e.g., about 50 mM) or propane sulfonic acid (e.g., about 50 mM) or any combination of the above.
In some embodiments of the invention, the pharmaceutical formulations of the present invention include a viscosity reducing agent, for example, arginine hydrochloride (e.g., L-arginine monohydrochloride) (e.g., 50 mM), lysine, sodium chloride (e.g., 40 mM or 50 mM), or magnesium chloride. Alternatively, in other embodiments, the formulations of the present invention specifically exclude substantially all, if not all, viscosity reducing agents.
In an embodiment of the invention, the pharmaceutical formulations of the present invention comprise, consists of or consists essentially of the constituents in any one of formulations A-KKKK as set forth herein.
In aspects herein, the pharmaceutical formulations of the present invention may include a VEGF receptor fusion protein (e.g., aflibercept or conbercept) at a concentration of from about 41 mg/ml to about 275 mg/ml, from about 80 mg/ml to about 275 mg/ml, about 140 mg/ml to about 150 mg/ml, about 140 mg/ml to about 159 or 160 mg/ml; including about 60 mg/ml, about 80 mg/ml, about 100 mg/ml, about 113.3 mg/ml, about 114.3 mg/ml, about 120 mg/ml, about 133.3 mg/ml, about 140 mg/ml, about 150 mg/ml, about 200 mg/ml or about 250 mg/ml. In an embodiment of the invention, the formulation comprises about 40 mg/ml of the VEGF receptor fusion protein.
Some aspects of the pharmaceutical formulations of the present invention include a thermal stabilizer at a concentration of from about 2% (w/v) to about 9% (w/v) or from about 4% (w/v) to about 9% (w/v), with the proviso, that when the thermal stabilizer is taurine or propane sulfonic acid, the stabilizer is at a concentration of from about 25 mM to about 100 mM, surfactant is at a concentration of from about 0.02% (w/v) to about 0.1% (w/v) (e.g., about 0.03%), and buffer is of from about 5 mM to about 15 mM.
The VEGF receptor fusion protein can, for example:
In another embodiment of the present invention, a container containing an aqueous solution of from about 5 mM to about 25 mM pharmaceutically acceptable buffer, from about 4% (w/v) to about 9% (w/v) of a pharmaceutically acceptable thermal stabilizer, from about 0.02% (w/v) to about 0.1% (w/v) of a pharmaceutically acceptable surfactant, and from about 41 mg/ml to about 275 mg/ml VEGF receptor fusion protein, is provided. When the thermal stabilizer includes either taurine or propane sulfonic acid, the taurine or propane sulfonic acid is at a concentration of from about 25 mM to about 100 mM. The aqueous solution has a pH of from about 5.0 to about 6.8, and can be from about 5.5 to about 6.2 (e.g., 5.8). In some aspects, the container is a vial or syringe. In other aspects, the aqueous solution does not include an inorganic salt. When the thermal stabilizer is a sugar it can be sucrose, mannitol, sorbitol or trehalose, and can be present at between about 4% (w/v) and 9% (w/v); the surfactant can be a non-ionic surfactant, and can include a polyoxyethylene moiety, such as polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350, at a concentration of from about 0.02% to about 0.1% weight per volume (w/v), and more typically, 0.02% to about 0.04% (w/v). In an embodiment of the invention, the VEGF receptor fusion protein is encoded by the nucleic acid sequence of SEQ ID NO:1 or nucleotides 79-1374 or 79-1371 of SEQ ID NO: 1; comprises amino acids of SEQ ID NO: 2 or amino acids 27-457 or 27-458 of SEQ ID NO: 2; comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO:2; and (3) a multimerization component (“FcΔC1(a)”) comprising amino acids 232 to 457 of SEQ ID NO:2 (the C-terminal amino acids of SEQ ID NO:2, i.e., K458, may or may not be included in the VEGF receptor fusion proteins); comprises an immunoglobin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1) and Ig domain 3 of a second VEGF receptor (e.g., VEGFR2), optionally further including an Ig domain 4 of the second VEGF receptor (e.g., VEGFR2) and a multimerizing component (e.g., Fc domain of IgG); is conbercept or is aflibercept.
In still other embodiments, pharmaceutical formulations of the present invention are provided having a VEGF receptor fusion protein in an aqueous vehicle, where the aqueous vehicle has a viscosity of from about 10 cP to about 15 cP at 20° C., more typically about 10 cP to about 13 cP at 20° C., and most typically from about 11 cP to about 12 cP at 20° C. (e.g., about 6.0, 7.3, 11.5 or 12.0 cP at 20° C.). In an embodiment of the invention, the viscosity is about 12 cP to about 15 cP at 20° C. The pH of the formulation can be from about 5.8 to about 6.5 (e.g., about 5.8). In some cases, the formulations do not include a viscosity reducing agent, for example, do not include arginine hydrochloride, lysine, sodium chloride, or magnesium chloride. In other cases, the formulations include 10 mM histidine hydrochloride or 10 mM histidine-acetate. The sugar can be sucrose, mannitol, sorbitol or trehalose, and can be present at between about 4% (w/v) and 9% (w/v) (e.g., about 5%); the surfactant can be a non-ionic surfactant, and can include a polyoxyethylene moiety, such as polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350, at a concentration of from about 0.02% to about 0.1% weight per volume (w/v), and more typically, 0.02% to about 0.04% (w/v) (e.g., 0.03%). In addition, the formulation can additionally include a thermal stabilizer selected from either taurine or propane sulfonic acid at a concentration of between about 25 mM to about 100 mM, and more typically about, 50 mM to about 70 mM. In an embodiment of the invention, a formulation comprises VEGF receptor fusion protein, such as aflibercept, (e.g., at a concentration of about 41-275 mg/ml, about 50 mg/ml, about 100 mg/ml, about 115 mg/ml, about 125 mg/ml, about 150 mg/ml, about 200 mg/ml or any of the “high” concentrations discussed herein), about 10 mM histidine-based buffer, about 5% (w/v) sucrose, about 0.03% (w/v) non-ionic surfactant such as polysorbate e.g., polysorbate 20, and about 50 mM arginine, L-arginine or L-arginine monohydrochloride, with a pH of about 5.8. In an embodiment of the invention, the VEGF receptor fusion protein is encoded by the nucleic acid sequence of SEQ ID NO:1 or nucleotides 79-1374 or 79-1371 of SEQ ID NO: 1; comprises amino acids of SEQ ID NO: 2 or amino acids 27-457 or 27-458 of SEQ ID NO: 2; comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO:2; and (3) a multimerization component (“FcΔC1(a)”) comprising amino acids 232 to 457 of SEQ ID NO:2 (the C-terminal amino acids of SEQ ID NO:2, i.e., K458, may or may not be included in the VEGF receptor fusion proteins); comprises an immunoglobin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1) and Ig domain 3 of a second VEGF receptor (e.g., VEGFR2), optionally further including an Ig domain 4 of the second VEGF receptor (e.g., VEGFR2) and a multimerizing component (e.g., Fc domain of IgG); is conbercept or is aflibercept.
In yet another embodiment, a pharmaceutical formulation of the present invention is provided that includes a VEGF receptor fusion protein at a concentration of from about 80 mg/ml to about 275 mg/ml in a pharmaceutically acceptable buffer. In some cases, the stable pharmaceutical formulations can also include taurine or propane sulfonic acid. The formulations can be stable at a temperature of about 2° C. to about 8° C. for about 24-36 months. In some cases, the VEGF receptor fusion protein shows less than about a 5% increase in high molecular weight species, and more typically, less than about 4.5% increase in high molecular weight species, less than about 4.0% increase in high molecular weight species, less than about 3.5% increase in high molecular weight species, less than about 3.0% increase in high molecular weight species, less than about 2.5% increase in high molecular weight species, less than about 2.0 increase in high molecular weight species and/or less than about 1.5% increase in high molecular weight species, when stored at these temperatures and for this amount of time. In other cases, the VEGF receptor fusion protein shows less than a 2.0% to 3.0% increase in high molecular weight species when the formulations are stored at these temperatures and for this amount of time.
Embodiments herein can also include pharmaceutical formulations of the present invention that include aflibercept, a pH buffered solution, a sugar and a surfactant, where the aflibercept is at a concentration of 41 mg/ml to about 275 mg/ml. Alternatively, embodiments can be stable liquid pharmaceutical formulations that include conbercept, a pH buffered solution, a sugar and a surfactant, where the conbercept is at a concentration of 41 mg/ml to about 275 mg/ml. Stable liquid pharmaceutical formulations can also include taurine or propane sulfonic acid. In some aspects, the aflibercept or conbercept is at a concentration of either 80 mg/ml or 150 mg/ml. In other aspects, the formulations do not include an inorganic salt, sodium chloride for example.
Some embodiments are directed to sterile syringes such that the syringes are pre-filled with an aqueous solution having 80 mg/ml aflibercept, conbercept, 10 mM histidine hydrochloride, histidine acetate or sodium phosphate, 5% (w/v) sucrose, mannitol, sorbitol or trehalose, 0.03% (w/v) polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350, and 40 mM sodium chloride. Aspects herein include the further addition of about 25 mM to about 100 mM, and more typically about 50 mM to about 70 mM, of either taurine or propane sulfonic acid. In some aspects, the syringes are pre-filled with an aqueous solution having 80 mg/ml aflibercept, conbercept, 10 mM histidine HCl, histidine acetate or sodium phosphate, 8% (w/v) sucrose, mannitol, sorbitol or trehalose, and 0.03% (w/v) polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350. Aspects herein include the further addition of about 25 mM to about 100 mM, and more typically about 50 mM to about 70 mM, of either taurine or propane sulfonic acid. In still other aspects, the syringes are pre-filled with an aqueous solution having 150 mg/ml aflibercept, conbercept, 10 mM histidine hydrochloride, histidine acetate, or sodium phosphate, 5% (w/v) sucrose, mannitol, sorbitol or trehalose, 0.03% (w/v) polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350 and 40 mM sodium chloride, with a pH of about 6.2. Aspects herein can include the further addition of either taurine or propane sulfonic acid. In yet still other aspects, the syringes are pre-filled with an aqueous solution having 150 mg/ml aflibercept, conbercept, 10 mM histidine hydrochloride, histidine acetate, or sodium phosphate, 8% (w/v) sucrose, mannitol, sorbitol or trehalose, and 0.03% (w/v) polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350, with a pH of about 6.2 and the aqueous solution does not include an inorganic salt. Aspects can further include about 25 mM to about 100 mM, and more typically, about 50 mM to about 70 mM, of either taurine or propane sulfonic acid. In yet still other aspects, the syringes are pre-filled with an aqueous solution having 150 mg/ml aflibercept or conbercept, 10 mM sodium acetate or acetic acid, 5% (w/v) glycerol and 0.03% (w/v) polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350 and 40 mM sodium chloride, with a pH of about 6.2. In yet still other aspects, the syringes are pre-filled with an aqueous solution having 150 mg/ml aflibercept or conbercept, 10 mM sodium acetate or acetic acid, 8% (w/v) glycerol, and 0.03% (w/v) polysorbate 20, polysorbate 80, poloxamer 188, or polyethylene glycol 3350 and 40 mM sodium chloride, with a pH of about 6.2.
The present invention also provides a method for making any formulation set forth herein comprising the step of combining each component of the formulation into a single composition. Such a method may include the step of adding the resulting formulation into a vial or injection device. Any composition that is the product of such a method also forms part of the present invention. For example, embodiments herein also include methods for preparing a formulation by combining a histidine-based, citrate-based, acetate-based or phosphate-based buffer, with sucrose, polysorbate 20 and a VEGF receptor fusion protein; and, optionally, one or more additional components, e.g., as discussed herein. In some cases, the formulation is prepared to also include taurine or propane sulfonic acid, but where it does not include taurine or propane sulfonic acid, it may also not include an inorganic salt. In aspects herein, the sucrose is at a weight per volume of from about 4% to about 10%, the polysorbate 20 has a weight per volume of about 0.02% to about 0.1%, and the receptor fusion protein is at a concentration of from about 41 mg/ml to about 275 mg/ml. Where the formulation includes taurine or propane sulfonic acid, it is present at, for example, about 25 mM to about 100 mM, but may also be included at 50 mM to 70 mM. The method can include loading a predetermined volume of prepared formulation into a sterile syringe, such that the volume has a 0.1 mg to 10 mg dose of the VEGF receptor fusion protein.
The present invention also provides a method for administering a formulation of the present invention to a subject (e.g., a human) comprising intraocularly injecting (e.g., intravitreal injection) the formulation into the eye of the subject. The present invention also provides a method for administering a formulation of the present invention to a subject (e.g., a human) comprising implanting an intravitreal implant that contains a formulation of the present invention into the vitreous of the subject.
Embodiments herein also include methods for treating an angiogenic eye disorder, e.g., age-related macular degeneration (wet), macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO) branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy or diabetic retinopathy (e.g., non-proliferative diabetic retinopathy and/or proliferative diabetic retinopathy) in a subject in need thereof by intraocularly injecting at least about 2 mg (e.g., 4 mg, 6 mg or 8 mg) of VEGF receptor fusion protein (e.g., aflibercept or conbercept) into the eye of a subject in need thereof, for example, any formulation set forth herein. In an embodiment of the invention, the injection volume is 100 microliters or less (e.g., 100 microliters, 50 microliters or 57 microliters). The method comprises an intravitreal injection of a pre-mixed aqueous solution having a VEGF receptor fusion protein at a concentration of from 41 mg/ml to about 275 mg/ml, a pharmaceutically acceptable sugar, a pharmaceutically acceptable buffer, and a pharmaceutically acceptable surfactant. Treatment methods using the pre-mixed aqueous solution do not require dilution. In aspects herein, the pre-mixed aqueous solution has a pH from about 6.0 and about 6.5, and has a viscosity of between about 10 cP and 13 cP.
In aspects of the treatment method, the VEGF receptor fusion protein comprises VEGFR1R2-FcΔC1(a) encoded by the nucleic acid sequence of SEQ ID NO:1, amino acids 27 to 129 of SEQ ID NO:2, a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO:2, or a multimerization component comprising amino acids 232 to 457 of SEQ ID NO:2, or any combination thereof. In an embodiment of the invention, the VEGF receptor fusion protein is aflibercept or conbercept.
Other embodiments in accordance with the disclosure herein will become apparent from a review of the ensuing detailed description.
The above and other aspects, features and advantages of embodiments disclosed herein will become more apparent to those of ordinary skill in the art with reference to the accompanying drawings.
The present invention provides formulations having high concentrations of VEGF receptor fusion proteins (e.g., aflibercept), showing excellent functional and storage properties which were developed in spite of significant technical hurdles. For example, a common method for identifying suitable excipients for a formulation that includes a polypeptide drug (such as a VEGF receptor fusion protein) is by assessment of polypeptide stability under accelerated stress conditions, such as high temperature (e.g., 37° C.). Excipients, which are not suitable under non-stress conditions (e.g., a low temperature such as 5° C.), will typically cause an undesired effect, within a short period of time, while under stress, e.g., protein aggregation. This approach is common in the biotechnology and pharmaceutical industry insofar as it expedites the elimination of excipients unlikely to stabilize the drug product. See e.g., Magari, Assessing Shelf Life Using Real-Time and Accelerated Stability Tests, Biopharm Intl. 16(11): 36-48 (2003). In some cases, a product may be released based on accelerated stability data, but this must be done in parallel with real-time shelf-life analysis (non-accelerated). Magari (2003) and FDA, Guidelines for Submitting Documentation for the Stability of Human Drugs and Biologics, Rockville, Md. (1987). Here, however, at 5° C., the presence of arginine in histidine formulations was stabilizing, though arginine, it appeared, tended to decrease stability when under temperature stress (37° C.). See
Reference will now be made in detail to representative embodiments. It should be understood that the following descriptions are not intended to limit the embodiments to one preferred embodiment. To the contrary, they are intended to cover alternatives, modifications, and equivalents as can be included within the spirit and scope of the described embodiments as defined in the appended claims.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. As used herein, the term “about,” when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. So for example, as used herein, the expression “about 100” includes 99 and 101 and all values in between (e.g., 99.1%, 99.2%, 99.3%, 99.4%, etc.).
In an embodiment of the invention, a pharmaceutical formulation of the present invention is compliant with USP<789> for small volume injection (SVP) of ophthalmic solutions, e.g., contains less than about 50 particles ≥10 μm in diameter per ml; contains less than about 5 particles ≥25 μm in diameter per ml; or contains less than about 2 particles ≥50 in diameter per ml.
Note that for purposes herein, “intravitreal injection” refers to injection into the vitreous of the eye (near the retina at the back of the eye). The expressions “suitable for intravitreal administration,” “suitable for intravitreal injection,” and the like mean that the formulation in question can be safely injected into the vitreous of a subject's eye without causing any adverse reactions beyond those known to be associated with intravitreal injection of EYLEA.
The term “pharmaceutical formulation” herein refers to formulations including pharmaceutically acceptable carriers, e.g., used to administer VEGF receptor fusion proteins (e.g., aflibercept or conbercept) to a subject for a therapeutic/medicinal use.
The term “pharmaceutically acceptable” refers to a formulation that within the scope of sound medical judgement is suitable for administration with the eye.
The term “subject” herein refers to any mammalian (e.g., rabbit, mouse, rat or monkey) subject, particularly a human, e.g., for whom diagnosis, prognosis or therapy is desired with the formulations as described herein.
The term “aqueous” formulation refers to a formulation which includes water.
The term “treat” or “treatment” refers to a therapeutic measure that reverses, stabilizes or eliminates an undesired disease or disorder (e.g., an angiogenic eye disorder or cancer), for example, by causing the regression, stabilization or elimination of one or more symptoms or indicia of such disease or disorder by any clinically measurable degree, e.g., with regard to an angiogenic eye disorder, by causing a reduction in or maintenance of diabetic retinopathy severity score (DRSS), by improving or maintaining vision (e.g., in best corrected visual acuity e.g., as measured by an increase in ETDRS letters), increasing or maintaining visual field and/or reducing or maintaining central retinal thickness and, with respect to cancer, stopping or reversing the growth, survival and/or metastasis of cancer cells in the subject. Typically, the therapeutic measure is administration of one or more doses of a therapeutically effective amount of VEGF receptor fusion protein to the subject with the disease or disorder.
“Prevent” or “prevention” refer to a prophylactic measure to cease the development of an undesired disease or disorder (e.g., an angiogenic eye disorder).
SE-UPLC can be used in the present invention to quantitate the presence of high molecular weight species in a formulation. SE refers to size exclusion chromatography. UPLC refers to ultra-performance liquid chromatography. Suitable SE columns, which may be used in a UPLC system, to characterize such HMW species of VEGF receptor fusion proteins (e.g., aflibercept or conbercept) in a formulation, are capable of resolving molecules in the molecular weight range of about 10,000-450,000 Daltons. See for example, the ACQUITY UPLC Protein BEH SEC 200 Å Column. In an embodiment of the invention, two of such columns are connected in tandem when quantitating HMW species in a formulation. UPLC brings improvements over HPLC (high performance liquid chromatography) in sensitivity and resolution. UPLC uses instrumentation that operates at high pressures and uses finer particles (typically less than about 2.5 μm) than that used in HPLC. Moreover, the UPLC mobile phases operate at high linear velocities than HPLC.
Embodiments herein include formulations that comprise a high concentration (e.g., about 60 mg/ml, about 80 mg/ml, about 90 mg/ml, about 100 mg/ml, about 113.3 mg/ml, about 114.3 mg/ml, about 120 mg/ml, about 133.3 mg/ml, about 140 mg/ml, about 150 mg/ml, about 200 mg/ml or about 250 mg/ml) of VEGF receptor fusion protein (e.g., aflibercept or conbercept). Suitable formulations included herein comprise a high concentration of VEGF receptor fusion protein, a buffer, a thermal stabilizer and a surfactant. In some aspects, a suitable formulation further includes a viscosity reducing agent. In other aspects, the suitable formulation substantially excludes all viscosity reducing agents. Typical formulations have a pH of from about 5.0 to about 6.8 (e.g., 5.8), but can include any pH useful for administration of the VEGF receptor fusion protein to the eye of a subject.
The present invention includes formulations that include a VEGF receptor fusion protein (e.g., aflibercept or conbercept) in association with one or more further therapeutic agents (e.g., an Ang-2 inhibitor (e.g., an anti-ANG2 antibody or antigen-binding fragment thereof or nesvacumab), a Tie-2 receptor activator, an anti-PDGF, PDGF receptor or PDGF receptor beta antibody or antigen-binding fragment thereof and/or an additional VEGF antagonist such as bevacizumab, ranibizumab, pegaptanib or a soluble form of human vascular endothelial growth factor receptor-3 (VEGFR-3) comprising extracellular domains 1-3, expressed as an Fc-fusion protein) as well as methods of prevention or treatment comprising administering such formulations as discussed herein. In an embodiment of the invention, a formulation of the present invention includes a VEGF receptor fusion protein, such as aflibercept, but excludes any further therapeutic agent (e.g., which is an antibody or antigen-binding fragment thereof).
The term “in association with” indicates that a formulation and a further therapeutic agent can be formulated into a single composition, e.g., for simultaneous delivery, or formulated separately into two or more compositions (e.g., a kit). The further therapeutic agent may, itself, be formulated in its own pharmaceutical formulation. Each can be administered to a subject at the same time as the other or at a different time than when the other is administered; for example, each administration may be given non-simultaneously (e.g., separately or sequentially) at intervals over a given period of time. Moreover, the formulation and the further therapeutic agent may be administered to a subject by the same or by a different route.
In an embodiment of the invention, a formulation of the present invention includes any one or more of sodium sulfate (e.g., 50 mM); sodium thiocyanate (e.g., 50 mM); sodium citrate (e.g., 40 mM); glycine (e.g., 50 mM); sodium chloride (e.g., 50 mM); lysine (e.g., 50 mM); sodium aspartate (e.g., 50 mM); and/or sodium glutamate (e.g., 50 mM). For example, in an embodiment the formulation comprises a combination of sodium citrate (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM); glycine (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM); sodium aspartate (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM); or sodium glutamate (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM).
VEGF Receptor Fusion Proteins and Other VEGF Inhibitors
For purposes herein, a “VEGF receptor fusion protein” refers to a molecule that comprises one or more VEGF receptors or domains thereof, fused to another polypeptide, which interferes with the interaction between VEGF and a natural VEGF receptor, e.g., wherein two of such fusion polypeptides are associated thereby forming a homodimer or other multimer. Such VEGF receptor fusion proteins may be referred to as a “VEGF-Trap” or “VEGF Trap”. VEGF receptor fusion proteins within the context of the present disclosure that fall within this definition include, chimeric polypeptides which comprise two or more immunoglobulin (Ig)-like domains of a VEGF receptor such as VEGFR1 (also known as Flt1) and/or VEGFR2 (also known as Flk1 or KDR), and may also contain a multimerizing domain (for example, an Fc domain).
An exemplary VEGF receptor fusion protein is a molecule referred to as VEGF1R2-FcΔC1(a) which is encoded by the nucleic acid sequence of SEQ ID NO:1 or nucleotides 79-1374 or 79-1371 thereof.
VEGF1R2-FcΔC1(a) comprises three components:
(1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2;
(2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO:2; and
(3) a multimerization component (“FcΔC1(a)”) comprising amino acids 232 to 457 of SEQ ID NO:2 (the C-terminal amino acids of SEQ ID NO:2, i.e., K458, may or may not be included in the VEGF receptor fusion proteins, see U.S. Pat. No. 7,396,664 or 7,354,579, incorporated herein for all purposes). Note that amino acids 1 to 26 of SEQ ID NO:2 are the signal sequence. In an embodiment of the invention, the VEGF receptor fusion protein comprises amino acids 27-458 or 27-457 of SEQ ID NO: 2.
In an embodiment of the invention, the VEGF receptor fusion protein comprises
(1) an immunoglobin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1), and
(2) an Ig domain 3 of a second VEGF receptor (e.g., VEGFR2),
(3) and, optionally, further including an Ig domain 4 of the second VEGF receptor (e.g., VEGFR2) and
(4) a multimerizing component (e.g., Fc domain of IgG).
For example, in an embodiment of the invention, the VEGF receptor fusion protein has the following arrangement of said domains:
In an embodiment of the invention, the VEGF receptor fusion protein is a VEGF mini-trap which is a VEGF trap molecule with a truncated multimerizing component (e.g., Fc), e.g., wherein the mini-trap still includes an Fc hinge region. See e.g., WO2005/00895 or U.S. Pat. No. 7,396,664.
Note that the present disclosure also includes, within its scope, high concentration formulations including, instead of a VEGF receptor fusion proteins, VEGF binding molecules and anti-VEGF antibodies and antigen-binding fragments thereof,
DARPins are Designed Ankyrin Repeat Proteins. DARPins generally contain three to four tightly packed repeats of approximately 33 amino acid residues, with each repeat containing a β-turn and two anti-parallel α-helices. This rigid framework provides protein stability whilst enabling the presentation of variable regions, normally comprising six amino acid residues per repeat, for target recognition.
An “anti-VEGF” antibody or antigen-binding fragment of an antibody refers to an antibody or fragment that specifically binds to VEGF.
Illustrative VEGF receptor fusion proteins include aflibercept (EYLEA®, Regeneron Pharmaceuticals, Inc.) or conbercept (sold commercially by Chengdu Kanghong Biotechnology Co., Ltd.). See International patent application publication no. WO2005/121176 or WO2007/112675. The terms “aflibercept” and “conbercept” include biosimilar versions thereof. A biosimilar version of a reference product (e.g., aflibercept) generally refers to a product comprising the identical amino acid sequence, but includes products which are biosimilar under the U.S. Biologics Price Competition and Innovation Act.
Pharmaceutical formulations of the present invention are “high concentration”. High concentration pharmaceutical formulations of the present invention include VEGF receptor fusion protein at a concentration of at least 41 mg/ml, of at least 80 mg/ml, of at least 100 mg/ml, of at least 125 mg/ml, of at least 140 mg/ml, of at least 150 mg/ml, of at least 175 mg/ml, of at least 200 mg/ml, of at least 225 mg/ml, of at least 250 mg/ml, or of at least 275 mg/ml. Alternatively, “high concentration” can refer to formulations that include a concentration of VEGF receptor fusion protein of from about 140 mg/ml to about 160 mg/ml, at least about 140 mg/ml but less than 160 mg/ml, from about 41 mg/ml to about 275 mg/ml, from about 70 mg/ml to about 75 mg/ml or from about 80 mg/ml to about 250 mg/ml. In some aspects, the VEGF receptor fusion protein concentration in the formulation is about any of the following concentrations: 41 mg/ml; 42 mg/ml; 43 mg/ml; 44 mg/ml; 45 mg/ml; 46 mg/ml; 47 mg/ml; 48 mg/ml; 49 mg/ml; 50 mg/ml; 51 mg/ml; 52 mg/ml; 53 mg/ml; 54 mg/ml; 55 mg/ml; 56 mg/ml; 57 mg/ml; 58 mg/ml; 59 mg/ml; 60 mg/ml; 61 mg/ml; 62 mg/ml; 63 mg/ml; 64 mg/ml; 65 mg/ml; 66 mg/ml; 67 mg/ml; 68 mg/ml; 69 mg/ml; 70 mg/ml; 71 mg/ml; 72 mg/ml; 73 mg/ml; 74 mg/ml; 75 mg/ml; 76 mg/ml; 77 mg/ml; 78 mg/ml; 79 mg/ml; 80 mg/ml; 81 mg/ml; 82 mg/ml; 83 mg/ml; 84 mg/ml; 85 mg/ml; 86 mg/ml; 87 mg/ml; 88 mg/ml; 89 mg/ml; 90 mg/ml; 91 mg/ml; 92 mg/ml; 93 mg/ml; 94 mg/ml; 95 mg/ml; 96 mg/ml; 97 mg/ml; 98 mg/ml; 99 mg/ml; 100 mg/ml; 101 mg/ml; 102 mg/ml; 103 mg/ml; 104 mg/ml; 105 mg/ml; 106 mg/ml; 107 mg/ml; 108 mg/ml; 109 mg/ml; 110 mg/ml; 111 mg/ml; 112 mg/ml; 113 mg/ml; 113.3 mg/ml; 114 mg/ml; 114.1 mg/ml; 114.2 mg/ml; 114.3 mg/ml; 114.4 mg/ml; 114.5 mg/ml; 114.6 mg/ml, 114.7 mg/ml, 114.8 mg/ml; 114.9 mg/ml; 115 mg/ml; 116 mg/ml; 117 mg/ml; 118 mg/ml; 119 mg/ml; 120 mg/ml; 121 mg/ml; 122 mg/ml; 123 mg/ml; 124 mg/ml; 125 mg/ml; 126 mg/ml; 127 mg/ml; 128 mg/ml; 129 mg/ml; 130 mg/ml; 131 mg/ml; 132 mg/ml; 133 mg/ml; 133.3 mg/ml; 133.4 mg/ml, 134 mg/ml; 135 mg/ml; 136 mg/ml; 137 mg/ml; 138 mg/ml; 139 mg/ml; 140 mg/ml; 141 mg/ml; 142 mg/ml; 143 mg/ml; 144 mg/ml; 145 mg/ml; 146 mg/ml; 147 mg/ml; 148 mg/ml; 149 mg/ml; 150 mg/ml; 151 mg/ml; 152 mg/ml; 153 mg/ml; 154 mg/ml; 155 mg/ml; 156 mg/ml; 157 mg/ml; 158 mg/ml; 159 mg/ml; 160 mg/ml; 161 mg/ml; 162 mg/ml; 163 mg/ml; 164 mg/ml; 165 mg/ml; 166 mg/ml; 167 mg/ml; 168 mg/ml; 169 mg/ml; 170 mg/ml; 171 mg/ml; 172 mg/ml; 173 mg/ml; 174 mg/ml; 175 mg/ml; 176 mg/ml; 177 mg/ml; 178 mg/ml; 179 mg/ml; 180 mg/ml; 181 mg/ml; 182 mg/ml; 183 mg/ml; 184 mg/ml; 185 mg/ml; 186 mg/ml; 187 mg/ml; 188 mg/ml; 189 mg/ml; 190 mg/ml; 191 mg/ml; 192 mg/ml; 193 mg/ml; 194 mg/ml; 195 mg/ml; 196 mg/ml; 197 mg/ml; 198 mg/ml; 199 mg/ml; 200 mg/ml; 201 mg/ml; 202 mg/ml; 203 mg/ml; 204 mg/ml; 205 mg/ml; 206 mg/ml; 207 mg/ml; 208 mg/ml; 209 mg/ml; 210 mg/ml; 211 mg/ml; 212 mg/ml; 213 mg/ml; 214 mg/ml; 215 mg/ml; 216 mg/ml; 217 mg/ml; 218 mg/ml; 219 mg/ml; 220 mg/ml; 221 mg/ml; 222 mg/ml; 223 mg/ml; 224 mg/ml; 225 mg/ml; 226 mg/ml; 227 mg/ml; 228 mg/ml; 229 mg/ml; 230 mg/ml; 231 mg/ml; 232 mg/ml; 233 mg/ml; 234 mg/ml; 235 mg/ml; 236 mg/ml; 237 mg/ml; 238 mg/ml; 239 mg/ml; 240 mg/ml; 241 mg/ml; 242 mg/ml; 243 mg/ml; 244 mg/ml; 245 mg/ml; 246 mg/ml; 247 mg/ml; 248 mg/ml; 249 mg/ml; 250 mg/ml; 251 mg/ml; 252 mg/ml; 253 mg/ml; 254 mg/ml; 255 mg/ml; 256 mg/ml; 257 mg/ml; 258 mg/ml; 259 mg/ml; 260 mg/ml; 261 mg/ml; 262 mg/ml; 263 mg/ml; 264 mg/ml; 265 mg/ml; 266 mg/ml; 267 mg/ml; 268 mg/ml; 269 mg/ml; 270 mg/ml; 271 mg/ml; 272 mg/ml; 273 mg/ml; 274 mg/ml; or 275 mg/ml. Other VEGF receptor fusion protein concentrations are contemplated herein, as long as the concentration functions in accordance with embodiments herein.
In an embodiment of the invention, a pharmaceutical formulation of the present invention is of such a concentration as to contain about 4, 6, 8, 10, 12, 14, 16, 18 or 20 mg VEGF receptor fusion protein (e.g., aflibercept), or the amount of such protein in any of the acceptable doses thereof which are discussed herein, in about 100 μl or less, about 75 μl or less or about 70 μl or less, e.g., about 50 μl; 51 μl; 52 μl; 53 μl; 54 μl; 55 μl; 56 μl; 57 μl; 58 μl; 59 μl; 60 μl; 61 μl; 62 μl; 63 μl; 64 μl; 65 μl; 66 μl; 67 μl; 68 μl; 69 μl; 70 μl; 71 μl; 72 μl; 73 μl; 74 μl; 75 μl; 76 μl; 77 μl; 78 μl; 79 μl; 80 μl; 81 μl; 82 μl; 83 μl; 84 μl; 85 μl; 86 μl; 87 μl; 88 μl; 89 μl; 90 μl; 91 μl; 92 μl; 93 μl; 94 μl; 95 μl; 96 μl; 97 μl; 98 μl; 99 μl; or 100 μl.
The present invention includes any of the formulations set forth under “Illustrative Formulations” herein, but wherein the concentration of the VEGF receptor fusion protein (e.g., aflibercept) is substituted with a concentration which is set forth in this section (“VEGF Receptor Fusion Proteins and Other VEGF inhibitors”).
Buffers
Buffers for use herein refer to solutions that resist pH change by use of acid-base conjugates. Buffers are capable of maintaining pH in the range of from about 5.0 to about 6.8, and more typically, from about 5.8 to about 6.5, and most typically, from about 6.0 to about 6.5. In some cases, the pH of the formulation of the present invention is about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, or about 6.8. Example buffers for inclusion in formulations herein include histidine-based buffers, for example, histidine, histidine hydrochloride, and histidine acetate. Buffers for inclusion in formulations herein can alternatively be phosphate-based buffers, for example, sodium phosphate, acetate-based buffers, for example, sodium acetate or acetic acid, or can be citrate-based, for example, sodium citrate or citric acid. It is also recognized that buffers can be a mix of the above, as long as the buffer functions to buffer the formulations in the above described pH ranges. In some cases, the buffer is from about 5 mM to about 25 mM, or more typically, about 5 mM to about 15 mM. Buffers can be about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, or about 25 mM.
In an embodiment of the invention, a histidine-based buffer is prepared using histidine and histidine monohydrochloride.
Surfactants
Surfactant for use herein refers to ingredients that protect the higher concentration of VEGF receptor fusion protein from various surface and interfacial induced stresses. As such, surfactants can be used to limit or minimize VEGF receptor fusion protein aggregation, and promote protein solubility. Suitable surfactants herein have been shown to be non-ionic, and can include surfactants that have a polyoxyethylene moiety. Illustrative surfactants in this category include: polysorbate 20, polysorbate 80, poloxamer 188, polyethylene glycol 3350, and mixtures thereof. Surfactants in the formulations can be present at from about 0.02% to about 0.1% weight per volume (w/v), and more typically, about 0.02% to about 0.04% (w/v). In some cases, the surfactant is about 0.02% (w/v), about 0.03% (w/v), about 0.04% (w/v), about 0.05% (w/v), about 0.06% (w/v), about 0.07% (w/v), about 0.08% (w/v), about 0.09% (w/v), or about 0.1% (w/v).
Thermal Stabilizers
Thermal stabilizers for use herein refers to ingredients that provide thermal stability against thermal denaturation of the VEGF receptor fusion protein, as well as protect against loss of VEGF receptor fusion protein potency or activity. Suitable thermal stabilizers include sugars, and can be sucrose, trehalose, sorbitol or mannitol, or can be amino acids, for example L-proline, L-arginine (e.g., L-arginine monohydrochloride), or taurine. Additionally, thermal stabilizers may also include substituted acrylamides or propane sulfonic acid, or may be compounds like glycerol.
In some cases, the formulations herein include both a sugar and taurine, a sugar and an amino acid, a sugar and propane sulfonic acid, a sugar and taurine, glycerol and taurine, glycerol and propane sulfonic acid, an amino acid and taurine, or an amino acid and propane sulfonic acid. In addition, formulations can include a sugar, taurine and propane sulfonic acid, glycerol, taurine and propane sulfonic acid, as well as L-proline, taurine and propane sulfonic acid.
Embodiments herein typically have thermal stabilizers present alone, each independently present at a concentration of, or present in combination at a total concentration of, from about 2% (w/v) to about 10% (w/v) or 4% (w/v) to about 10% (w/v), or about 4% (w/v) to about 9% (w/v), or about 5% (w/v) to about 8% (w/v). Thermal stabilizers in the formulation can be at a concentration of about 2% (w/v), about 2.5% (w/v), about 3% (w/v), about 4% (w/v), about 5% (w/v), about 6% (w/v), about 7% (w/v), about 8% (w/v), about 9% (w/v), about 10% (w/v) or about 20% (w/v).
With respect to taurine and propane sulfonic acid, in an embodiment of the invention, these thermal stabilizers can be present in the formulations at about from 25 mM to about 100 mM, and more typically from about 50 mM to about 75 mM (as compared to the other thermal stabilizers).
Viscosity Reducing Agents
Viscosity reducing agents typically are used to reduce or prevent protein aggregation. Viscosity reducing agents for inclusion herein include: sodium chloride, magnesium chloride, D- or L-arginine (e.g., L-arginine monohydrochloride), lysine, or mixtures thereof. When present herein, viscosity reducing agents can be present at from about 10 mM to about 100 mM, and more typically from about 30 mM to about 75 mM, and even more typically from about 40 mM to about 70 mM. In some cases the viscosity reducing agent is present at about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM or about 100 mM.
Formulation Viscosity
Formulations in accordance with embodiments herein can also have a pharmaceutically acceptable viscosity for ocular administration, for example, intravitreal injection. Viscosity generally refers to the measure of resistance of a fluid which is being deformed by either shear stress or tensile stress (typically measured by techniques known in the art, viscometer or rheometer, for example). Typical viscosities of formulations in accordance with embodiments herein are from about 5.0 cP (centipoise) to about 15 cP, from about 11 cP to about 14 cP, from about 12 cP to about 15 cP or from about 11 cP to about 12 cP. As such, formulation viscosity herein can be about 5.0 cP, about 6.0, about 7.1 cP, about 7.2 cP, about 7.3 cP, about 7.4 cP, about 7.5 cP, about 7.6 cP, about 10 cP, about 10.5 cP, about 11.0 cP, about 11.5 cP, about 12.0 cP, about 12.5 cP, about 13.0 cP, about 13.5 cP, about 14.0 cP, about 14.5 cP, or about 15.0 cP (e.g., when measured at 20° C.).
Various embodiments herein do not require inclusion of an inorganic salt, or other viscosity reducing agent, to maintain these highly useful viscosities. Typically, high concentration protein solutions require viscosity reducing agents to avoid protein aggregation and higher viscosity, making the formulations difficult for intravitreal injection and reducing the potency of the VEGF receptor fusion protein. As such, embodiments herein include formulations that have had substantially no, or no added, sodium chloride (NaCl), magnesium chloride (MgCl2), D- or L-arginine hydrochloride, lysine or other viscosity reducing agent.
Formulation Osmolality
Osmolality is a critical attribute for injectable formulations. It is desirable to have products match physiological osmotic conditions. Furthermore, osmolality provides confirmation of soluble content in solution. In an embodiment of the invention, the osmolality of a formulation of the present invention is less than or equal to about 506 mmol/Kg or from about 250 to about 506 mmol/Kg., e.g., about 250, 260, 270, 280, 290, 299, 300, 310, 314, 315, 316, 324, 343, 346, 349, 369, 384, 403, 426, 430 or 506 mmol/Kg. In an embodiment of the invention, the osmolality is lower than about 250 mmol/Kg.
Purity and Stability of Formulations
High concentration VEGF receptor fusion protein containing formulations described herein are stable during manufacture and storage. The term “stable” herein refers to formulations that include VEGF receptor proteins that retain both chemical and physical stability over the period of formulation manufacturing and storage, e.g., that maintains integrity and has minimal degradation, denaturation, or unfolding. VEGF receptor protein stability can be determined using analytical techniques available in the art at different temperatures and over different periods of time. In particular, VEGF receptor chemical stability (potency) can be determined using various bioassays (for example, a BAF/3 VEGFR1/EPOR cell line used to determine VEGF 165 binding by the VEGF receptor fusion proteins herein), and physical stability, by size exclusion (SE) chromatographic analysis, UPLC (ultra-performance liquid chromatography) size exclusion (SE) chromatography, visual appearance, OD, pH, charge variant formation, and rate of high molecular weight (HMW) species formation. A stable VEGF receptor fusion protein is one that shows limited change in its OD, pH, formation of charge variants, and formation of HMW species.
A “high molecular weight” (HMW) species as used herein, with reference to a formulation containing a given VEGF Trap (e.g., aflibercept), refers to any species of polypeptide or polypeptide complex in the formulation which elutes from a size exclusion column (e.g., SE-UPLC) ahead of (e.g., with a higher molecular weight than) VEGF Trap polypeptide and/or a homodimer thereof. The percentage of HMW species refers to the percentage of such species relative to the overall quantity of polypeptides in the formulation, e.g., by SE-UPLC analysis.
In an embodiment of the invention, as discussed more fully in the Examples below, stable formulations show significant VEGF receptor fusion protein potency and physical stability for a period of up to 12 months, up to 24 months, and/or up to 36 months when stored at about 2° C. to about 8° C.
In an embodiment of the invention, formulation of the present invention is one that:
and/or
Further, in an embodiment of the invention, high concentration VEGF receptor fusion proteins are stable as they show little or no formation of acidic charge variants over the course of manufacture and storage, for example, little or no formation of charge variants as tested by Imaged Capillary Isoelectric Focusing, for example.
In an embodiment of the invention, a formulation of the present invention exhibits less than or equal to about 8% low molecular weight (LMW) species.
In an embodiment of the invention, a formulation of the present invention has less than about 0.2, 0.4 or 0.5 EU (endotoxin units)/ml of endotoxin;
In an embodiment of the invention, a formulation of the present invention is essentially free of particulate matter or particulate matter of about 1, 2, 5, 10, 25 or 50 micrometers (or more) in size.
In an embodiment of the invention, when a formulation of the present invention is analyzed by non-reduced CE-SDS (SDS capillary gel electrophoresis), at least 97% of the total peak area is the main peak.
In an embodiment of the invention, when a formulation of the present invention is analyzed by size-exclusion UPLC (SE-UPLC), at least 93, 94 or 95% of the total peak area is the main peak and less than or equal to 3.5, 4, 5 or 6% is aggregate.
In an embodiment of the invention, a formulation of the present invention is at about 2° C., 3° C., 4° C., 5° C., 6° C., 7° C. or 8° C., 2-8° C. (e.g., an average temperature of 5° C.), 23° C., 25° C., 30° C. or 37° C.
Illustrative Formulations
Illustrative high concentration VEGF receptor fusion protein containing formulations include the following:
Formulation A: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation B: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation C: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation D: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2.
Formulation E: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation F: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation G: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation H: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation I: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation J: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation K: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation L: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation M: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation N: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation O: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation P: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2.
Formulation Q: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation R: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation S: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation T: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2 (e.g., 6.2), and, optionally, specifically excluding a viscosity reducing agent.
Formulation U: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation V: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation W: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation X: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation Y: 80 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation Z: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation AA: 80 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation BB: 80 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2.
Formulation CC: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation DD: 80 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation EE: 80 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation FF: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation GG: 80 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation HH: 80 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation II: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation JJ: 80 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation KK: 150 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation LL: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation MM: 150 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation NN: 150 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2.
Formulation OO: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation PP: 150 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.
Formulation QQ: 150 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation RR: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation SS: 150 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation TT: 150 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation UU: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation VV: 150 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2, and, optionally, specifically excluding a viscosity reducing agent.
Formulation WW: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM taurine, with a pH of 5.8.
Formulation XX: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 4% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8.
Formulation YY: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM taurine, with a pH of 5.8.
Formulation ZZ: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8.
Formulation AAA: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM PSA, with a pH of 5.8.
Formulation BBB: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM PSA, with a pH of 5.8.
Formulation CCC: 80, 100, 120 or 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8.
Formulation DDD: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10 mM histidine-based buffer, 4% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM PSA, with a pH of 5.8.
Formulation EEE: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 5% (w/v) sucrose, and 0.03% (w/v) polysorbate 20 and, optionally, no thermal stabilizer, with a pH of 5.8.
Formulation FFF: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10 mM sodium phosphate, 5% (w/v) sucrose and 0.03% polysorbate 20 with a pH of 6.2.
Formulation GGG: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium sulfate
Formulation HHH: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium thiocyanate
Formulation III: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 40 mM sodium citrate
Formulation JJJ: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% Sucrose, 0.03% polysorbate 20; 50 mM glycine
Formulation KKK: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 50 mM sodium chloride
Formulation LLL: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM lysine
Formulation MMM: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate
Formulation NNN: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate
Formulation OOO: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium citrate; 50 mM arginine hydrochloride
Formulation PPP: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM glycine; 50 mM arginine hydrochloride
Formulation QQQ: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; 50 mM arginine hydrochloride
Formulation RRR: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; 50 mM arginine hydrochloride
Formulation SSS: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 10 mM L-arginine hydrochloride
Formulation TTT: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept); 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 100 mM L-arginine hydrochloride
Formulation UUU: 30 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
Formulation VVV: 30 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
Formulation WWW: 60 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
Formulation XXX: 60 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
Formulation YYY: 120 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
Formulation ZZZ: 120 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
Formulation AAAA: 120 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2
Formulation BBBB: 120 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2
Formulation CCCC: 140 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 10 mM sodium phosphate, 5% sucrose, 40 mM sodium chloride, 0.03% PS20, pH 6.2
Formulation DDDD: 80 mg/ml VEGF receptor fusion protein (e.g., aflibercept), 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8.
Formulation EEEE: 120.0 mg/ml VEGF receptor fusion protein (e.g., aflibercept) (e.g., ±12 mg/ml), 20 mM histidine-based buffer (e.g., ±2 mM), 5% (w/v) sucrose (e.g., ±0.5%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine monohydrochloride (e.g., ±5 mM), with a pH of 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
Formulation FFFF: 113.3 mg/ml VEGF receptor fusion protein (e.g., aflibercept) (e.g., 102-125 mg/ml), 20 mM histidine-based buffer (e.g., ±2 mM), 5% (w/v) sucrose (e.g., ±0.5%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine monohydrochloride (e.g., ±5 mM), with a pH of 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
Formulation GGGG: 114.3 mg/ml VEGF receptor fusion protein (e.g., aflibercept) (e.g., 103-126 mg/ml), 10 mM histidine-based buffer (e.g., ±1 mM), 5% (w/v) sucrose (e.g., ±0.5%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine monohydrochloride (e.g., ±5 mM), with a pH of 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
Formulation HHHH: 100.0 mg/ml VEGF receptor fusion protein (e.g., aflibercept) (e.g., ±10 mg/ml), 20 mM histidine-based buffer (e.g., ±2 mM), 5% (w/v) sucrose (e.g., ±0.5%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine monohydrochloride (e.g., ±5 mM), with a pH of 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
Formulation IIII: 133.3 mg/ml VEGF receptor fusion protein (e.g., aflibercept) (e.g., ±13 mg/ml), 20 mM histidine-based buffer (e.g., ±2 mM), 5% (w/v) sucrose (e.g., ±0.5%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine monohydrochloride (e.g., ±5 mM), with a pH of 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
Formulation JJJJ: 150 mg/ml aflibercept (e.g., aflibercept) (e.g., ±15 mg/ml), 10 mM sodium phosphate, 8% (w/v) sucrose (e.g., ±0.8%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%) and 50 mM L-arginine hydrochloride, pH 6.2 (e.g., 6.0-6.4 or 5.9-6.5).
Formulation KKKK: 114.3 mg/ml VEGF receptor fusion protein (e.g., aflibercept) (e.g., ±14 mg/ml), 20 mM histidine-based buffer (e.g., ±2 mM), 5% (w/v) sucrose (e.g., +0.5%), 0.03% (w/v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine monohydrochloride (e.g., +5 mM), with a pH of 5.8 (e.g., 5.6-6.0 or 5.5-6.1);
or any formulation which is set forth herein.
In an embodiment of the invention, the concentration of any formulation constituent (e.g., all constituents) listed above (e.g., any one of formulations A-KKKK) or which is discussed herein is ±about 3%, 5% or about 10% of the concentration specifically mentioned.
Methods of Manufacture
Embodiments herein include methods of manufacturing a pharmaceutical formulation of the present invention including a VEGF receptor fusion protein (e.g., any of formulations A-KKKK as set forth herein) comprising combining the components of the formulation into a single composition, and, optionally, introducing the formulation into a vessel or device e.g., a vial, or delivery device, e.g., a pre-filled syringe. The formulations, vials or devices that are the product of such methods are part of the present invention.
In an embodiment of the invention, the method of manufacturing a VEGF receptor fusion protein containing pharmaceutical formulation of the present invention (e.g., any of formulations A-KKKK as set forth herein) comprises the steps of culturing a host cell (e.g., Chinese hamster ovary cell) comprising one or more polynucleotides encoding a VEGF receptor fusion protein (e.g., aflibercept) in a culture medium and under conditions whereby the protein is expressed; and, purifying the protein from the host cell and/or culture medium and combining a portion of the protein with excipients of a pharmaceutical formulation as set forth herein. Again, the formulations, vials or devices that are the product of such methods are part of the present invention.
In an embodiment of the invention, a determination is made as to the amount and type of VEGF receptor fusion protein needed in the formulation to make it a high concentration and for its end-use. The same determination is made regarding the amount and type of buffer, the amount and type of surfactant, the amount and type of thermal stabilizer, and the inclusion, or specific exclusion, of a viscosity reducing agent. These components are combined and mixed, making sure that the formulation pH is at the desired value, e.g., between about 5.0 and about 6.8 (e.g., 5.8), and/or that the viscosity is at a desired value, e.g., about 6.0, 7.3, 11.5 or 12.0 cP at 20° C. In an embodiment of the invention, high concentration VEGF receptor fusion protein containing formulations can be sterilized and stored in a stable condition, e.g., for up to 24 or 36 months at 2° C. to 8° C. (e.g., 5° C.).
See, e.g., Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y.; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, N.Y.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY; Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, N.Y.
Angiogenic Eye Disorders and Cancer
The pharmaceutical formulations of the present invention comprising VEGF receptor fusion proteins (e.g., any of pharmaceutical formulations A-KKKK) can be used in the treatment or prevention of any angiogenic eye disorder by administration of a therapeutically effective amount of VEGF receptor fusion protein in a formulation of the present invention to a subject in need thereof, e.g., by intravitreal injection. Angiogenic eye disorders herein refer to any disease of the eye which is caused by or associated with the growth or proliferation of blood vessels and/or by blood vessel leakage. Non-limiting examples of angiogenic eye disorders that are treatable or preventable using the formulations and methods herein, include:
The pharmaceutical formulations of the present invention comprising VEGF receptor fusion proteins (e.g., any of pharmaceutical formulations A-KKKK) can be used in the treatment or prevention of any cancer by administration of a therapeutically effective amount of VEGF receptor fusion protein in a formulation of the present invention to a subject in need thereof, e.g., by intramuscular, intratumoral, subcutaneous or intravenous injection. Cancers include those whose growth, proliferation, survival and/or metastasis is dependent, to a degree, on angiogenesis. In an embodiment of the invention, the cancer is colorectal cancer, lung cancer, skin cancer, breast cancer, brain cancer, stomach cancer, renal cancer, prostate cancer, liver cancer or pancreatic cancer.
Thus, the present invention provides methods for treating or preventing an angiogenic eye disorder in a subject in need thereof comprising administering a therapeutically effective amount of VEGF receptor fusion protein (e.g., aflibercept) (e.g., about 4, 6, or 8.0, 8.1, 8.4 or 8.5 mg), e.g., in a pharmaceutical formulation according to the present invention, intraocularly, e.g., into the vitreous, of an eye of the subject. In an embodiment of the invention, both eyes are administered the VEGF receptor fusion protein. In an embodiment of the invention, therapeutically effective doses of the VEGF receptor fusion protein are administered about every 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks 18 weeks, 19 weeks, 20 weeks, 21, weeks, 22 weeks, 23 weeks or 24 weeks. In an embodiment of the invention, such methods of treatment or prevention are done in the absence of significant increases in blood pressure (systolic and/or diastolic) and/or the development of hypertension (e.g., Grade 1, Grade 2 or Grade 3) and/or abnormally high intraocular pressure in the subject. In an embodiment of the invention, the method includes the step of, following said administration, monitoring the subject for significant increases in blood pressure (systolic and/or diastolic) and/or the development of hypertension (e.g., Grade 1, Grade 2 or Grade 3) and/or abnormally high intraocular pressure.
Modes of Administration
The pharmaceutical formulations of the present invention which include a VEGF receptor fusion protein may be administered in accordance with known medically approved delivery systems. In embodiments herein, these delivery systems may include administering the formulations to the patient by ocular, intraocular, intrachoroidal, intravitreal or subconjunctival injection. Alternatively, pharmaceutical formulations of the present invention can also be administered to the patient by topical routes, e.g., eye drops, eye gels, eye ointments, and the like. Other possible routes of delivery for the formulations herein include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral.
In an embodiment of the invention, intravitreal injection of a pharmaceutical formulation of the present invention includes the step of piercing the eye with a syringe and needle (e.g., 30-gauge injection needle) containing the formulation and injecting the formulation (e.g., less than or equal to about 100 microliters; about 40, 50, 55, 56, 57, 57.1, 58, 60, 70 or 75 microliters) into the vitreous of the eye (e.g., with a sufficient volume as to deliver a therapeutically effective amount of VEGF receptor fusion protein, e.g., of about 4, 5, 6, 7, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8 or 8.9, 9, 10, 12, 14, 16, 18 or 20 mg VEGF receptor fusion protein). Optionally, the method includes the steps of administering a local anesthetic (e.g., proparacaine, lidocaine or tetracaine), an antibiotic (e.g., a fluoroquinolone), antiseptic (e.g., povidone-iodine) and/or a pupil dilating agent to the eye being injected. In an embodiment of the invention, a sterile field around the eye to be injected is established before the injection. In an embodiment of the invention, following intravitreal injection, the subject is monitored for elevations in intraocular pressure and/or blood pressure. In an embodiment of the invention, the other eye is also injected by the same procedure.
Amounts of VEGF Receptor Fusion Protein to be Administered
Each dose of high concentration VEGF receptor fusion protein to a subject over the course of a treatment may contain the same or substantially the same amount of fusion protein. Alternatively, the quantity of any one dose may be different or variable over a treatment course.
An effective or therapeutically effective amount of VEGF receptor fusion protein for treating or preventing cancer (e.g., which is mediated, at least in part, by angiogenesis) or an angiogenic eye disorder refers to the amount of the VEGF receptor fusion protein sufficient to cause the regression, stabilization or elimination of the cancer or angiogenic eye disorder, e.g., by regressing, stabilizing or eliminating one or more symptoms or indicia of the cancer or angiogenic eye disorder by any clinically measurable degree, e.g., with regard to an angiogenic eye disorder, by causing a reduction in or maintenance of diabetic retinopathy severity score (DRSS), by improving or maintaining vision (e.g., in best corrected visual acuity e.g., as measured by an increase in ETDRS letters), increasing or maintaining visual field and/or reducing or maintaining central retinal thickness and, with respect to cancer, stopping or reversing the growth, survival and/or metastasis of cancer cells in the subject. In an embodiment of the invention, an effective or therapeutically effective amount of VEGF receptor fusion protein for treating or preventing an angiogenic eye disorder is about 0.5 mg to about 10 mg or 0.5 mg to about 20 mg per dose, including: about 0.5 mg or more; or about 2 mg or more, e.g., about 2.1 mg; 2.2 mg; 2.3 mg; 2.4 mg; 2.5 mg; 2.6 mg; 2.7 mg; 2.8 mg; 2.9 mg; 3.0 mg; 3.1 mg; 3.2 mg; 3.3 mg; 3.4 mg; 3.5 mg; 3.6 mg; 3.7 mg; 3.8 mg; 3.9 mg; 4.0 mg; 4.1 mg; 4.2 mg; 4.3 mg; 4.4 mg; 4.5 mg; 4.6 mg; 4.7 mg; 4.8 mg; 4.9 mg; 5.0 mg; 5.1 mg; 5.2 mg; 5.3 mg; 5.4 mg; 5.5 mg; 5.6 mg; 5.7 mg; 5.8 mg; 5.9 mg; 6.0 mg; 6.1 mg; 6.2 mg; 6.3 mg; 6.4 mg; 6.5 mg; 6.6 mg; 6.7 mg; 6.8 mg; 6.9 mg; 7.0 mg; 7.1 mg; 7.2 mg; 7.3 mg; 7.4 mg; 7.5 mg; 7.6 mg; 7.7 mg; 7.8 mg; 7.9 mg; 8.0 mg; 8.1 mg; 8.2 mg; 8.3 mg; 8.4 mg; 8.5 mg; 8.6 mg; 8.7 mg; 8.8 mg; 8.9 mg; 9 mg; 9.1 mg; 9.2 mg; 9.3 mg; 9.4 mg; 9.5 mg; 9.6 mg; 9.7 mg; 9.8 mg; 9.9 mg, 10.0 mg, 10.1 mg; 10.2 mg; 10.3 mg; 10.4 mg; 10.5 mg; 10.6 mg; 10.7 mg; 10.8 mg; 10.9 mg; 11 mg; 11.1 mg; 11.2 mg; 11.3 mg; 11.4 mg; 11.5 mg; 11.6 mg; 11.7 mg; 11.8 mg; 11.9 mg; 12 mg; 12.1 mg; 12.2 mg; 12.3 mg; 12.4 mg; 12.5 mg; 12.6 mg; 12.7 mg; 12.8 mg; 12.9 mg; 13 mg; 13.1 mg; 13.2 mg; 13.3 mg; 13.4 mg; 13.5 mg; 13.6 mg; 13.7 mg; 13.8 mg; 13.9 mg; 14 mg; 14.1 mg; 14.2 mg; 14.3 mg; 14.4 mg; 14.5 mg; 14.6 mg; 14.7 mg; 14.8 mg; 14.9 mg; 15 mg; 15.1 mg; 15.2 mg; 15.3 mg; 15.4 mg; 15.5 mg; 15.6 mg; 15.7 mg; 15.8 mg; 15.9 mg; 16 mg; 16.1 mg; 16.2 mg; 16.3 mg; 16.4 mg; 16.5 mg; 16.6 mg; 16.7 mg; 16.8 mg; 16.9 mg; 17 mg; 17.1 mg; 17.2 mg; 17.3 mg; 17.4 mg; 17.5 mg; 17.6 mg; 17.7 mg; 17.8 mg; 17.9 mg; 18 mg; 18.1 mg; 18.2 mg; 18.3 mg; 18.4 mg; 18.5 mg; 18.6 mg; 18.7 mg; 18.8 mg; 18.9 mg; 19 mg; 19.1 mg; 19.2 mg; 19.3 mg; 19.4 mg; 19.5 mg; 19.6 mg; 19.7 mg; 19.8 mg; 19.9 mg; or 20 mg. In an embodiment of the invention, an effective or therapeutically effective amount of VEGF receptor fusion protein for treating or preventing cancer is about 4 mg/kg (e.g., intravenously). This dose may be administered, for example, every 2 weeks.
In an embodiment of the invention, a VEGF receptor fusion protein is administered in a volume sufficient to deliver the desired dose of fusion protein, e.g., as discussed above. In an embodiment of the invention, the volume delivered (e.g., for treating or preventing an angiogenic eye disorder, e.g., by intravitreal injection) is less than or equal to about 100 microliters (e.g., about any of the following volumes: 25 microliters; 26 microliters; 27 microliters; 28 microliters; 29 microliters; 30 microliters; 31 microliters; 32 microliters; 33 microliters; 34 microliters; 35 microliters; 36 microliters; 37 microliters; 38 microliters; 39 microliters; 40 microliters; 41 microliters; 42 microliters; 43 microliters; 44 microliters; 45 microliters; 46 microliters; 47 microliters; 48 microliters; 49 microliters; 50 microliters; 51 microliters; 52 microliters; 53 microliters; 54 microliters; 55 microliters; 56 microliters; 57 microliters; 58 microliters; 59 microliters; 60 microliters; 61 microliters; 62 microliters; 63 microliters; 64 microliters; 65 microliters; 66 microliters; 67 microliters; 68 microliters; 69 microliters; 70 microliters; 71 microliters; 72 microliters; 73 microliters; 74 microliters; 75 microliters; 76 microliters; 77 microliters; 78 microliters; 79 microliters; 80 microliters; 81 microliters; 82 microliters; 83 microliters; 84 microliters; 85 microliters; 86 microliters; 87 microliters; 88 microliters; 89 microliters; 90 microliters; 91 microliters; 92 microliters; 93 microliters; 94 microliters; 95 microliters; 96 microliters; 97 microliters; 98 microliters or 99 microliters).
In an embodiment of the invention, the formulation is administered (e.g., for treating or preventing an angiogenic eye disorder, e.g., by intravitreal injection) in a volume which is about 60 microliters or less, about 70 microliters or less or about 75 microliters or less or about 100 microliters or less. For example, in an embodiment of the invention, about 2, 4, 6, 8.0, 8.1, 8.0-8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8 or 8.9, 9.0 or 10 mg of VEGF receptor fusion protein is administered in about 50, 60, 70 or 75 microliters.
The scope of the present invention also encompasses methods for delivering 0.5 or 2 mg of VEGF receptor fusion protein (e.g., for treating or preventing an angiogenic eye disorder, e.g., by intravitreal injection) in pharmaceutical formulation of the present invention in a low volume such as less than 50 μl (e.g., about 1, 5, 10, 17, 17.5, 18, 18.5, 20, 30, 40 or 45 μl).
The present invention also includes a composition including or consisting or consisting essentially of a “single dosage volume” of pharmaceutical formulation of the present invention, i.e., a volume containing a single dose of VEGF receptor fusion protein (e.g., aflibercept) in a pharmaceutical formulation of the present invention (e.g., about 50 μl or 60 μl, 70 μl or 75 μl or whatever volume contains about 4, 6, 8 or 10 mg of VEGF receptor fusion protein). As discussed below, a container (e.g., vial or injection device) comprising a single dosage volume, optionally including a small overfill volume of formulation, is also part of the present invention.
Containers and Injection Devices
High concentration VEGF receptor fusion protein formulations in accordance with embodiments herein (e.g., any of formulations A-KKKK) can be pre-packaged or pre-loaded in various useful containers and injection devices. Thus, the present invention includes containers and injection devices containing such formulations. In one embodiment herein, the container is a vial which may be sterile. In another embodiment herein, the container is a test tube which may be sterile. In an embodiment of the invention, an injection device (which may be sterile) is a syringe (e.g., a pre-filled syringe or autoinjector). In an embodiment of the invention, the injection device is an intravitreal implant, e.g., a refillable intravitreal implant.
A “pre-filled” syringe is a syringe which is filled with a formulation of the present invention prior to sale or use by the physician or patient.
“Sterile” herein refers to aseptic or free from substantially all, or all, living microorganisms and their spores.
Syringes as used herein include barrels made, for example, of glass or polymer, for example, cycloolefin as described in U.S. Patent Publication No. 2017/0232199, incorporated herein for all purposes, a plunger and a needle.
Containers and injection devices may be coated with silicone (e.g., silicone oil or baked-silicone (e.g., ≤40 μg or ≤100 μg)).
In an embodiment of the invention, a container or injection device is substantially metal-free or substantially tungsten-free or low-tungsten.
In an embodiment of the invention, the syringe contains one or more dose line graduations and/or is a dose metering system.
Containers in accordance with embodiments herein can hold the high concentration VEGF receptor fusion protein formulations. In some aspects, the container or injection device can include a label stating indications of use. In some instances, the container or injection device herein can include package inserts with instructions for use as described throughout this specification.
In other embodiments, a volume containing a single dose or multiple doses (e.g., 2 or more than 2) of a high concentration VEGF receptor fusion protein (e.g., wherein the dose is 2 mg, 4 mg, 6 mg, 8 mg or 10 mg of VEGF receptor fusion protein), as described above, can be pre-packaged into a container or injection device, e.g., a sterile syringe, for example, for storage until use. In one example, the volume in the container includes a single dose of VEGF receptor fusion protein optionally further including a small amount of overfill volume. Sterile, pre-loaded syringes can be maintained under storage conditions (e.g., 2° C.-8° C.), for example, for up to 12 months, 24 months or 36 months. Overfill is an excess volume that is meant to be sufficient to permit withdrawal and/or administration of the proper volume. In an embodiment of the invention, the container has a single dosage volume or multiple dosage volumes and about 5%-10% overfill volume.
Syringe sizes can be, for example, 0.3 cc, 0.5 cc or 1 cc, for example. Sterile syringes typically include a needle useful for ocular injection, typically about ½ inch, or 12.5 mm to 16 mm in length, and can be 29 gauge, 30 gauge, 31 gauge, 32 gauge or 33 gauge based on the patient and health care specialist preference. Other needle lengths and gauges can be used, as long as the needle is effective at accomplishing intravitreal injection.
While the invention has been particularly shown and described with reference to a number of embodiments, it would be understood by those skilled in the art that changes in the form and details may be made to the various embodiments disclosed herein without departing from the spirit and scope of the invention and that the various embodiments disclosed herein are not intended to act as limitations on the scope of the claims.
Additional Formulations
The present invention includes the following formulations comprising greater than 40 mg/ml VEGF receptor fusion protein (e.g., aflibercept or conbercept) and:
(a) a buffer including a histidine salt (e.g., histidine-HCl or histidine-acetate, for example, 10 mM to 50 mM) and having pH ranging from 5.7 to 6.2; a sugar (e.g., more than 6%, but not more than 10%) such as sucrose, trehalose, mannitol or glucose; a surfactant selected from the group consisting of polysorbate 20 and polysorbate 80 (e.g., 0% to 0.1%);
(b) a histidine containing buffer such as L-histidine/histidine hydrochloride (e.g., 10 mM); a non-ionic surfactant such as polysorbate 20 (e.g., 0.03%), an inorganic salt such as NaCl (e.g., 40 mM), and a carbohydrate such as sucrose (e.g., 5%), e.g. pH 6.0-6.5 (e.g., 6.2 or 6.5);
(c) citric acid (e.g., 5 mM, 10 mM, 15 mM, 20 mM, 25 mM or 30 mM), sucrose (e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%), arginine (e.g., 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM or 50 mM or 100 mM), and polysorbate 20 (e.g., 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.10%);
(d) a buffer such as phosphate, histidine, acetate, succinate, citrate, glutamate, and/or lactate (e.g., at 5-20 or 5-50 mM); a non-ionic surfactant such as a polysorbate (e.g., PS20 or PS80), a polyethylene glycol dodecyl ether, a poloxamer, Tetramethylbutyl)phenyl-polyethylene glycol, an alkylsaccharide or an alkylglycoside, a tonicifying agent such as a polyol or an amino acid, for example, sucrose, trehalose, sorbitol, mannitol, glycerol, proline, arginine, methionine, glycine, or lysine, wherein the formulation has a final osmolality of about 300 mOsm/kg, and wherein the concentration of chloride anion is less than about 10 mM; pH 5.0-6.5; or
(e) 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2.
The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention. Efforts have been made to ensure accuracy with respect to numbers used, but some experimental errors and deviations should be accounted for. Any formulations set forth in these examples are part of the present invention.
In these examples, when an experiment is conducted at 2-8° C., the temperature is targeted to 5° C. with a tolerance of ±3° C. variation.
A series of four different formulations having 80 mg/ml VEGF receptor fusion protein (aflibercept) were tested for long term potency, physical stability and development of charge variants. The ingredient listing of each of the four formulations is shown in Table 1-1. Each formulation was evaluated for VEGF receptor fusion protein HMW species formation over the course of storage at 2° C. to 8° C. for 36 months, as well as for the percent main species by SE-UPLC. Each VEGF receptor fusion protein containing formulation was also evaluated using Imaged Capillary Isoelectric Focusing over the same course of time and temperature. Finally, each formulation's potency was tested by bioassay over the same course of time and temperature.
Data is shown in
Referring to
The data in Example 1 shows that formulations having double the VEGF TRAP concentration found in EYLEA®, can maintain physical stability, quality and potency over the course of 36 months at 2° to 8° C. Further, although all four formulations showed similar potency over the period, histidine containing formulations resulted in a slightly smaller increase in HMW species formation (sign of protein degradation), showing that under some circumstances, histidine may be a buffer of choice. However, the findings for both histidine and phosphate based buffers showed excellent stability over the course of the study.
Two sodium phosphate formulations were tested for physical stability of 150 mg/ml VEGF Trap (aflibercept) at 37° C. for 28 days. The ingredient listing of each of the two formulations is shown in Table 2-1. Each formulation was evaluated for HMW species formation over the course of storage at 37° C. for the 28 days as well as for the percent main species by SE-UPLC.
The results were then compared to formulations that included 40 mg/ml EYLEA®, and Formulation 1 from Example 1 (80 mg/ml VEGF TRAP in sodium phosphate buffer). As expected, the 150 mg/ml VEGF TRAP formulations showed a higher percent of HMW species formation as compared to the EYLEA® formulation, and a somewhat higher percent of HMW species formation as compared to Formulation 1 of Example 1.
Further testing was performed on high concentration VEGF TRAP containing formulations, and histidine containing formulations showed better protection of these molecules than did formulations based in sodium phosphate. Further, inclusion of sodium chloride into each of the tested formulations actually caused destabilization of the VEGF TRAP at 37° C. The data in Example 2 shows that even at high concentrations of 150 mg/ml VEGF receptor fusion protein, and fairly extreme temperature storage, the formulations herein provide excellent protection for physical stability.
A number of VEGF Trap (aflibercept) containing formulations were tested for their viscosity behavior. Formulations having from between 10 mg/ml to 160 mg/ml VEGF Trap were tested in the presence and absence of various viscosity reducing agents.
Two sodium phosphate formulations were tested for physical stability of 150 mg/ml VEGF Trap (aflibercept) at 2-8° C. for 12 months. The ingredient listing of each of the two formulations is shown in Table 4-1. Formulation 2 further includes 50 mM arginine hydrochloride. Each formulation was evaluated for HMW species formation over the course of storage at 37° C. for the 12 months as well as for the percent main species by SE-UPLC.
An experiment was conducted to determine the effect on protein stability with a number of formulation combinations.
A total of 9 different aflibercept formulations were tested with varying buffer concentration, thermal stabilizers and hydrophobic salts. The 9 formulations, F1-F9, are summarized below in Table 7-1.
Fourteen (14) mL of each formulation was compounded in 15 mL Falcon tubes. The formulation was then sterile filtered using a 0.22 μM syringe filter and filled in sterile 2 mL Type 1 glass vials. Eight (8) vials were filled for each formulation with 0.4 mL volume in a laminar flow hood.
SE-UPLC (molecular weight species) was performed on all samples to determine the chemical stability of each formulation.
The percentage of HMW species over time for each of formulations F1-F9 are shown in
The impact of varying the concentration of arginine-HCl on the stability of four 140 mg/mL VEGF Trap (aflibercept) eye drug product formulations was studied. The evaluation of stability was performed at the storage condition of 2-8° C. The drug product (DP) was also incubated under stress (37° C.) conditions. The four formulations being evaluated in this stability study (F1-F4) are described in Table 8-1 set forth below.
Approximately 145 mL of 187 mg/mL VEGF Trap histidine formulations were thawed. Thirty six (36) mL of each formulation, with the exception of F3, was compounded; 39 mL of bulk F3 was compounded. Each formulation was filter sterilized within a LFH (laminar flow hood) using a 0.22 μm Durapore PVDF sterilizing filter prior to filling. Clean depyrogenated 2 mL type I Schott glass vials stoppered with 13 mm serum stoppers (S2-F451 4432/50B2-40) were used to perform stability studies.
SE-UPLC analysis of the formulations was performed as set forth above. The % HMW measurements, using SE-UPLC, in each formulation over time are set forth in
When stored at 5° C., these formulations exhibited a reduction in the rate of formation of % HMW species that was proportional to the concentration of arginine-HCl. Under stress, however, this effect was reversed. The formulations, at 37° C., exhibited an apparent increase in % HMW species proportional to the concentration of arginine-HCl. This property made the discovery of arginine's beneficial effects on aflibercept in the presence of histidine buffer highly unlikely. Typically, for formulation development in the biotechnology industry, the effect of various excipients on a drug is initially screened under stress (e.g., at elevated temperature such as 37° C.) for a short period of time. The purpose of this approach it to rapidly eliminate excipients which will not likely perform well in the absence of stress (e.g., at lower temperature such as 5° C.) over a longer period of time. Here, arginine was identified as a helpful excipient in spite of its effect on stability at 37° C. Since formulated drug product is typically stored for months at 4-5° C. after manufacture, aflibercept in arginine and histidine buffer would be a highly valuable formulation for long term, stable drug product storage.
The effect of various counterions and other excipients on stability of several formulations was determined.
A. Counterion Screening
Counter ions (e.g., sulfate, thiocyanate and citrate) were tested in the form of sodium salts with high concentration VEGF Trap (aflibercept) formulations (140 mg/ml). Additionally, other amino add excipients (e.g., glycine and lysine) were also tested.
Approximately 42 ml of 187 mg/ml VEGF Trap eye drug substance were thawed. 50 ml of intermediate formulated drug substance (155.56 mg/ml), having a 110% concentration of the 140 mg/ml formulated drug substance and target excipient concentration (excluding the counterions, glycine and lysine), were prepared.
The intermediate formulated drug substance was further diluted with the 0.5 M stock excipient solutions (counterions, glycine or lysine) to produce the 140 mg/ml formulated drug substance formulations listed in Table 9-1 below. Each final formulation was filter sterilized with a 0.22 μm PVDF syringe filter within a laminar flow hood prior to filling into clean depyrogenated 2 mL type I Schott glass vials stoppered with 13 mm serum stoppers S2-F451 4432/50 82-40 (ELN item #19700004 Wash #0 000078949). Sixty (60) vials were filled with 0.5 ml of each formulation. Six (6) vials were filled with 1.5 ml.
B. Glutamate and Aspartate Screening
The stability of VEGF Trap (aflibercept) high concentration formulations (140 mg/ml) in the presence of organic counter ions in combination with arginine hydrochloride was tested. In addition, two new counter ions (glutamate and asparate) were tested for compatibility with high concentration VEGF Trap (in combination and without arginine hydrochloride). The formulations tested are summarized below in Table 9-2.
Approximately 50 ml of 187 mg/ml VEGF Trap drug substance were thawed. 60 ml of intermediate formulated drug substance (155.56 mg/ml) with a 110% of the 140 mg/ml formulated drug substance and target excipient concentration (excluding the counterions, citrate, glycine, glutamate and aspartate) was prepared. The intermediate formulated drug substance was further diluted with the 1M stock excipient solutions (arginine hydrochloride, sodium citrate, glycine, sodium glutamate and sodium aspartate) to produce the 140 mg/ml formulated drug substance formulations listed in the table below. Each final formulation was filter sterilized with a 0.22 μm PVDF syringe filter within a laminar flow hood prior to filling into clean depyrogenated 2 ml type I Schott glass vials stoppered with 13 mm serum stoppers S2-F451 4432/50 B2-40 (ELN item #19700004 Wash #0000078949). Sixty (60) vials were filled with 0.5 ml of each formulation. Six (6) vials were filled with 1.5 ml.
Viscosity testing was performed using a RHEOSENSE m-VROC® viscometer. Approximately, 0.5 mL of undiluted sample was loaded onto a glass syringe. The sample was equilibrated to the desired temperature and injected into a chip or measuring cell. Viscosity was calculated by measuring the pressure drop from inlet to the outlet which is correlated to the shear-stress at the wall of the chip. Results are expressed as mPas-1 or cp. See
Osmolality testing was performed using a VAPRO vapor pressure osmometer. Approximately, 10 μL of undiluted sample was inoculated into a paper disc. The dew point temperature depression, a function of the solution vapor pressure, was measured through a sensitive thermocouple and reported as osmolality of the solution. Results are expressed as mmol/kg or mOsm. See
High molecular weight species in certain formulations over time, after storage at 37° C. or 5° C., was also evaluated by SE-UPLC. See
Dynamic light scattering experiments were performed using a DynaPro® Plate Reader II. Approximately, 100 μL of undiluted sample was loaded onto a 96-well plate. Thirty five acquisitions were obtained for each well at 25° C. Analysis of autocorrelation function using regularization was performed on the DYNAMICS v7.1 software. Radius (nm) vs % intensity plots and % mass vs radius (nm) plots were generated to derive the average molecular radius and % polydispersity values (% Pd) for each sample. See
Anti-VEGF therapeutics, administered via intravitreal injection, are currently the standard of care for treatment of neovascular age-related macular degeneration, diabetic macular edema, and retinal vascular occlusive disease. However, the monthly or bi-monthly intravitreal injections represent a significant treatment burden on patients, caregivers, and physicians. There is a pressing need for more effective and durable therapies in clinical practice. This study is to investigate the tolerability of stably formulated high dose VEGF Trap (140 mg/ml, equivalently 14 folds of the clinical dose) in normal New Zealand white rabbit eyes.
Two formulations of high dose VEGF-Trap (aflibercept) in histidine buffer or in phosphate buffer were tested. Three rabbits per cohort received 7 mg of VEGF Trap in 50 uL by single bilateral intravitreal injection of each formulation. Ocular inflammation signs were monitored by slit lamp, optical coherence tomography (OCT) and fundus angiograph at day 1, day 4, week 1 then weekly until 12 weeks post-intravitreal administration. Intraocular pressure was measured with Tonopen before and 10 minutes and 30 minutes post intravitreal injection, then at every follow up time point. Animals were euthanized at week 12.
The rabbit eyes were dosed with either:
Two of six eyes from the histidine buffer group showed dark shadows in the vitreous until 8 weeks post IVT, which were confirmed by slit-lamp examination as local cataract due to posterior lens injury, procedure related. One of 6 eyes the from phosphate buffer group showed dark shadows in the vitreous until 8 weeks post IVT, which were confirmed by slit-lamp examination as local cataract due to posterior lens injury (procedure related).
The high dose VEGF Trap (140 mg/ml) formulations tested were well tolerated in normal New Zealand White rabbit eyes within 12 weeks post-single intravitreal administration. After a single intravitreal injection of 7 mg of VEGF Trap, no signs of abnormalities or inflammation were seen in the fundus. The vitreous was clear and the retinal vascular pattern appeared normal. No retinal detachment, hemorrhage or optic nerve head changes were seen. There was no intraocular pressure change compared to baseline. The baseline fluorescein angiography (FA) and OCT images of rabbit eyes are represented in
This study examined the stability of 60 mg/ml and 120 mg/ml VEGF Trap (aflibercept) in 10 mM phosphate, 10% or 20% sucrose (Suc.), 0 or 50 mM NaCl, 0.03% polysorbate 20, pH 6.2 when incubated at 37° C. for up to 6 months. The formulations for this stability study are set forth below in Table 11-1.
The formulation was filter sterilized with a PVDF 0.2 μm filter in a laminar flow hood prior to dispensing.
Vials containing each formulation were stored at 37° C. for 1 month.
All of the formulations were essentially particle-free by visual inspection and optical density measurement. There was no significant protein loss in recovery by RP-HPLC after 1 month at 37° C. (Table 11-2) and this trend continued out to 6 months.
The main degradation pathway for VEGF Trap was aggregation under these conditions (
The safety of various formulations in cynomolgus monkeys is assessed in this example. A total of 7 intravitreal doses are administered to both eyes approximately Q4W to Groups 1-3; a total of 3 intravitreal doses are administered to both eyes approximately Q4W to groups 4-9. A terminal necropsy is performed approximately one week after last dose (N=3/sex/group) with recovery necropsy (2/sex/group) approximately 12-week after last dose
The following assessments are performed:
It is expected that the formulations tested in any one or more of Groups 1, 2, 3, 4, 5, 6, 7, 8 and/or 9 will be determined to have a safety profile comparable to EYLEA in cynomolgous monkeys as measured in the assessments discussed above.
A formulation including 114.3 mg/mL VEGF Trap (aflibercept) and 10 mM Histidine, pH 5.8, 5% Sucrose, 0.03% Polysorbate 20, 50 mM Arginine Monohydrochloride was prepared within a LFH (laminar flow hood) using a 0.22 μm Durapore PVDF sterilizing filter prior to filling. Clean depyrogenated 3 mL type I Schott glass vials were filled with 0.3 mL of Drug Product and stoppered with 13 mm serum stoppers (S2-F451 4432/50B2-40). Samples were analyzed at various timepoints after storage at 37° C. or 5° C. for purity by size-exclusion chromatography (SEC) to determine the presence (%) of high molecular weight species (HMW), low molecular weight species (LMW) and the main peak (main); as well as microflow imaging, HIAC liquid particle counting (by light obscuration) and microscopically to determine the presence of particles of various sizes.
Stability and purity data after storage at 37° C., 25° C. and 2-8° C. are shown in
The impact of varying the concentration of VEGF Trap on the stability of four VEGF Trap (aflibercept) eye drug product formulations was studied. The concentrations ranged between 80 and 140 mg/mL. The evaluation of stability was performed at the storage condition of 2-8° C. The drug product (DP) was also incubated under stress (37° C.) conditions. The four formulations (each of which is named “CCC” herein) being evaluated in this stability study are described in Table 14-1 set forth below.
Approximately 27 mL of each formulation was prepared within a LFH (laminar flow hood) using a 0.22 μm Durapore PVDF sterilizing filter prior to filling. Clean depyrogenated 2 mL type I Schott glass vials were filled and stoppered with 13 mm serum stoppers (S2-F451 4432/50B2-40). Samples were analyzed at various timepoints after storage at 37° C. or 2-8° C. for purity by size-exclusion-ultraperformance liquid chromatography (SE-UPLC) to determine the presence (%) of high molecular weight species (HMW) and the main peak (main).
Data showing the percentage HMW after incubation at 2-8° C. or 37° C. for up to 6 months are set forth in
The effect of a four-fold increase in dose on duration of action of aflibercept to inhibit chronic retinal vascular leak in the D,L-AAA model was determined in this Example.
Animals used were New Zealand White rabbits 3 months post-DL-AAA (DL-α-aminoadipic acid) disease induction. The treatment groups were:
The formulation used in each treatment group was: 10 mM Histidine, 8% sucrose, 0.03% PS20, pH 5.8. Ophthalmic exams, which were performed at baseline and at weeks 1, 2, 4, 6, 7, 9, 10, 11, 13 and 18, were intra-ocular pressure (TOP), red-free (RF) imaging (to determine blood vessel morphology), fluorescein angiography (FA; to determine vascular leak), optical coherence tomography (OCT; to identify vitreal inflammation). Serum (ADA) and plasma (drug levels) were collected at baseline and at weeks 1, 2, 4, 6 and 9.
Data from FA exams of each group are set forth in
This application is a continuation of U.S. application Ser. No. 16/409,631, filed May 10, 2019, now U.S. Pat. No. 11,103,552, which claims the benefit of U.S. Provisional Patent Application No. 62/813,882, filed Mar. 5, 2019; U.S. Provisional Patent Application No. 62/769,876, filed Nov. 20, 2018; U.S. Provisional Patent Application No. 62/752,127, filed Oct. 29, 2018; and U.S. Provisional Patent Application No. 62/669,506, filed May 10, 2018; each of which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
5580856 | Prestrelski et al. | Dec 1996 | A |
6136346 | Eljamal et al. | Oct 2000 | A |
6171586 | Lam et al. | Jan 2001 | B1 |
6267958 | Andya et al. | Jul 2001 | B1 |
6358530 | Eljamal et al. | Mar 2002 | B1 |
6582729 | Eljamal et al. | Jun 2003 | B1 |
6586574 | Hansen | Jul 2003 | B1 |
6652875 | Bannister | Nov 2003 | B1 |
6685940 | Andya et al. | Feb 2004 | B2 |
6833349 | Xia et al. | Dec 2004 | B2 |
6875432 | Liu et al. | Apr 2005 | B2 |
7060268 | Andya et al. | Jun 2006 | B2 |
7070959 | Papadopoulous | Jul 2006 | B1 |
7087411 | Daly et al. | Aug 2006 | B2 |
7279159 | Daly et al. | Oct 2007 | B2 |
7303746 | Wiegand et al. | Dec 2007 | B2 |
7303747 | Wiegand et al. | Dec 2007 | B2 |
7306799 | Wiegand et al. | Dec 2007 | B2 |
7374757 | Papadopoulos et al. | May 2008 | B2 |
7374758 | Papadopoulos et al. | May 2008 | B2 |
7396664 | Daly et al. | Jul 2008 | B2 |
7399612 | Daly et al. | Jul 2008 | B2 |
7521049 | Wiegand et al. | Apr 2009 | B2 |
7524499 | Papadopoulos et al. | Apr 2009 | B2 |
7608261 | Furfine et al. | Oct 2009 | B2 |
7635474 | Daly et al. | Dec 2009 | B2 |
7648702 | Gombotz et al. | Jan 2010 | B2 |
7682609 | Andya et al. | Mar 2010 | B2 |
7704500 | Papadopoulos et al. | Apr 2010 | B2 |
7807164 | Furfine et al. | Oct 2010 | B2 |
7851443 | Bissery et al. | Dec 2010 | B2 |
7956160 | Krishnan et al. | Jun 2011 | B2 |
7964377 | Papadopoulos et al. | Jun 2011 | B2 |
7972598 | Daly et al. | Jul 2011 | B2 |
8029791 | Papadopoulos et al. | Oct 2011 | B2 |
8084234 | Papadopoulos et al. | Dec 2011 | B2 |
8092803 | Furfine et al. | Jan 2012 | B2 |
8110546 | Dix et al. | Feb 2012 | B2 |
8216575 | Yu | Jul 2012 | B2 |
8343737 | Papadopoulos et al. | Jan 2013 | B2 |
8372396 | Andya et al. | Feb 2013 | B2 |
8404638 | Dix et al. | Mar 2013 | B2 |
8481046 | Furfine et al. | Jul 2013 | B2 |
8568720 | Morichika et al. | Oct 2013 | B2 |
8623395 | de Juan, Jr. et al. | Jan 2014 | B2 |
8647842 | Papadopoulos et al. | Feb 2014 | B2 |
8710004 | Dix et al. | Apr 2014 | B2 |
8802107 | Furfine et al. | Aug 2014 | B2 |
8921316 | Dix et al. | Dec 2014 | B2 |
8961964 | Liu et al. | Feb 2015 | B2 |
9139644 | Papadopoulos et al. | Sep 2015 | B2 |
9254338 | Yancopoulos | Feb 2016 | B2 |
9283273 | Andya et al. | Mar 2016 | B2 |
9340594 | Furfine et al. | May 2016 | B2 |
9402898 | Walsh et al. | Aug 2016 | B2 |
9416167 | Dix et al. | Aug 2016 | B2 |
9474803 | Park et al. | Oct 2016 | B2 |
9511140 | Dix et al. | Dec 2016 | B2 |
9580489 | Furfine et al. | Feb 2017 | B2 |
9636400 | Dix et al. | May 2017 | B2 |
9669069 | Yancopoulos | Jun 2017 | B2 |
9708386 | Papadopoulos et al. | Jul 2017 | B2 |
9884019 | Tchessalov et al. | Feb 2018 | B2 |
9914763 | Furfine et al. | Mar 2018 | B2 |
9982032 | Park et al. | May 2018 | B2 |
10130681 | Yancopoulos | Nov 2018 | B2 |
10166293 | Liu et al. | Jan 2019 | B2 |
10392430 | Papadopoulos et al. | Aug 2019 | B2 |
10400025 | Furfine et al. | Sep 2019 | B2 |
10406226 | Dix et al. | Sep 2019 | B2 |
10413513 | Fabio et al. | Sep 2019 | B2 |
10464992 | Furfine et al. | Nov 2019 | B2 |
10501523 | Chiron-Blondel et al. | Dec 2019 | B2 |
10576128 | Sigl | Mar 2020 | B2 |
10610600 | Soane et al. | Apr 2020 | B2 |
10689438 | Zhang et al. | Jun 2020 | B2 |
10799642 | Wong et al. | Oct 2020 | B2 |
10828345 | Yancopoulos | Nov 2020 | B2 |
10857205 | Yancopoulos | Dec 2020 | B2 |
10857231 | Dix et al. | Dec 2020 | B2 |
10869924 | Andrews et al. | Dec 2020 | B2 |
10888601 | Yancopoulos | Jan 2021 | B2 |
10898572 | Kameoka et al. | Jan 2021 | B2 |
10925927 | Brockmeyer et al. | Feb 2021 | B2 |
10973879 | Vitti et al. | Apr 2021 | B2 |
11033606 | Castan | Jun 2021 | B2 |
11053278 | Blum et al. | Jul 2021 | B2 |
11066458 | Furfine et al. | Jul 2021 | B2 |
11077059 | Coffman et al. | Aug 2021 | B2 |
11077188 | Kauvar et al. | Aug 2021 | B2 |
11084865 | Furfine et al. | Aug 2021 | B2 |
11103552 | Graham et al. | Aug 2021 | B2 |
11110226 | Bryant et al. | Sep 2021 | B2 |
11123411 | Borodic | Sep 2021 | B2 |
11135266 | Kerwin et al. | Oct 2021 | B2 |
11160881 | Rangaramanujam et al. | Nov 2021 | B2 |
11179521 | Bryant et al. | Nov 2021 | B2 |
11185635 | Bryant et al. | Nov 2021 | B2 |
11209444 | Baldwin et al. | Dec 2021 | B2 |
11241498 | Tang et al. | Feb 2022 | B2 |
11253572 | Yancopoulos et al. | Feb 2022 | B2 |
11351256 | Tang et al. | Jun 2022 | B2 |
11459374 | Tustian et al. | Oct 2022 | B2 |
11505593 | Wang et al. | Nov 2022 | B2 |
11534396 | Blizzard et al. | Dec 2022 | B2 |
11542317 | Wang et al. | Jan 2023 | B1 |
11559564 | Yancopoulos | Jan 2023 | B2 |
11596667 | Rezaei | Mar 2023 | B2 |
11666632 | Brockmeyer et al. | Jun 2023 | B2 |
11667702 | Liu et al. | Jun 2023 | B2 |
11692027 | Kraft et al. | Jul 2023 | B2 |
11707506 | Yancopoulos | Jul 2023 | B2 |
11730794 | Yancopoulos | Aug 2023 | B2 |
11732024 | Furfine et al. | Aug 2023 | B2 |
11806398 | Dix et al. | Nov 2023 | B2 |
11958894 | Wang et al. | Apr 2024 | B2 |
11975045 | Yancopoulos | May 2024 | B2 |
11986511 | Yancopoulos | May 2024 | B2 |
12005097 | Kerwin et al. | Jun 2024 | B2 |
20030113316 | Kaisheva et al. | Jun 2003 | A1 |
20030138417 | Kaisheva et al. | Jul 2003 | A1 |
20030180287 | Gombotz et al. | Sep 2003 | A1 |
20030206939 | Bannister | Nov 2003 | A1 |
20040197324 | Liu et al. | Oct 2004 | A1 |
20040266686 | Xia et al. | Dec 2004 | A1 |
20050013867 | Lehrman et al. | Jan 2005 | A1 |
20050032699 | Holash et al. | Feb 2005 | A1 |
20050112061 | Holash et al. | May 2005 | A1 |
20050123509 | Lehrman et al. | Jun 2005 | A1 |
20050196340 | Holash et al. | Sep 2005 | A1 |
20060217311 | Dix et al. | Sep 2006 | A1 |
20070053900 | Liu et al. | Mar 2007 | A1 |
20070172479 | Warne et al. | Jul 2007 | A1 |
20070190058 | Shams | Aug 2007 | A1 |
20070237758 | Barry et al. | Oct 2007 | A1 |
20080064856 | Warne et al. | Mar 2008 | A1 |
20080071063 | Allan et al. | Mar 2008 | A1 |
20090280129 | Liu et al. | Nov 2009 | A1 |
20100158899 | Andya et al. | Jun 2010 | A1 |
20100254985 | Allan et al. | Oct 2010 | A1 |
20110028698 | Papadopoulos et al. | Feb 2011 | A1 |
20110236383 | Andya et al. | Sep 2011 | A1 |
20120114646 | Tchessalov et al. | May 2012 | A1 |
20120121580 | Bhambhani et al. | May 2012 | A1 |
20120183531 | Lucas et al. | Jul 2012 | A1 |
20130029909 | Ryan et al. | Jan 2013 | A1 |
20130058958 | Bowen et al. | Mar 2013 | A1 |
20130084635 | Papadopoulos et al. | Apr 2013 | A1 |
20130236448 | Kamerzell et al. | Sep 2013 | A1 |
20130295094 | Yancopoulos | Nov 2013 | A1 |
20130323242 | Everett et al. | Dec 2013 | A1 |
20140051642 | Castan | Feb 2014 | A1 |
20140294816 | Shima et al. | Oct 2014 | A1 |
20140348852 | Vos et al. | Nov 2014 | A1 |
20150150982 | Michael et al. | Jun 2015 | A1 |
20150157709 | Everett et al. | Jun 2015 | A1 |
20150182623 | Everett et al. | Jul 2015 | A1 |
20150202288 | Shima et al. | Jul 2015 | A1 |
20150209431 | Ma et al. | Jul 2015 | A1 |
20160144025 | Vitti et al. | May 2016 | A1 |
20160244504 | Dix et al. | Aug 2016 | A1 |
20160340420 | Zhang et al. | Nov 2016 | A1 |
20160375133 | Bhambhani et al. | Dec 2016 | A1 |
20160376342 | Park et al. | Dec 2016 | A1 |
20170051039 | Gombotz et al. | Feb 2017 | A1 |
20170073407 | Dix et al. | Mar 2017 | A1 |
20170209582 | Park et al. | Jul 2017 | A1 |
20180055940 | Ma et al. | Mar 2018 | A1 |
20180099049 | Tang et al. | Apr 2018 | A1 |
20180221280 | Fabio et al. | Aug 2018 | A1 |
20180289623 | Chen et al. | Oct 2018 | A1 |
20180298092 | Gekkiva et al. | Oct 2018 | A1 |
20180326126 | Fiedler | Nov 2018 | A1 |
20180333493 | Shenoy | Nov 2018 | A1 |
20190000919 | Brockmeyer et al. | Jan 2019 | A1 |
20190060241 | Patel et al. | Feb 2019 | A1 |
20190144523 | Gombotz et al. | May 2019 | A1 |
20190160145 | Im et al. | May 2019 | A1 |
20190275021 | Jiang et al. | Sep 2019 | A1 |
20190290725 | Vitti et al. | Sep 2019 | A1 |
20190298801 | Kerwin et al. | Oct 2019 | A1 |
20190343918 | Graham et al. | Nov 2019 | A1 |
20190358323 | Liu et al. | Nov 2019 | A1 |
20200017572 | Furfine et al. | Jan 2020 | A1 |
20200046834 | Tang et al. | Feb 2020 | A1 |
20200108064 | Horn et al. | Apr 2020 | A1 |
20200114002 | Soane et al. | Apr 2020 | A1 |
20200131246 | Furfine et al. | Apr 2020 | A1 |
20200155678 | Chen et al. | May 2020 | A1 |
20200206028 | Boschetti et al. | Jul 2020 | A1 |
20200214888 | Bryant et al. | Jul 2020 | A1 |
20200230237 | Kauvar et al. | Jul 2020 | A1 |
20200237862 | Sigl | Jul 2020 | A1 |
20200237997 | Brockmeyer et al. | Jul 2020 | A1 |
20200246423 | Liu et al. | Aug 2020 | A1 |
20200253875 | Coffman et al. | Aug 2020 | A1 |
20200255496 | Wexler-Cohen et al. | Aug 2020 | A1 |
20200281923 | Wang | Sep 2020 | A1 |
20200283492 | Lee et al. | Sep 2020 | A1 |
20200338164 | Wexler-Cohen et al. | Oct 2020 | A1 |
20200353041 | Ferrara et al. | Nov 2020 | A1 |
20200390693 | Kim et al. | Dec 2020 | A1 |
20200390724 | Arkin et al. | Dec 2020 | A1 |
20200390725 | Arkin et al. | Dec 2020 | A1 |
20200397729 | Tempesta et al. | Dec 2020 | A1 |
20210000758 | Arkin et al. | Jan 2021 | A1 |
20210008158 | Hohman et al. | Jan 2021 | A1 |
20210008199 | Zhang et al. | Jan 2021 | A1 |
20210023173 | Yancopoulos | Jan 2021 | A1 |
20210077624 | Dix et al. | Mar 2021 | A1 |
20210085753 | Yancopoulos | Mar 2021 | A1 |
20210100856 | Gasmi et al. | Apr 2021 | A1 |
20210115124 | Koenig et al. | Apr 2021 | A1 |
20210121524 | Yancopoulos | Apr 2021 | A1 |
20210138032 | Silva Leal et al. | May 2021 | A1 |
20210138034 | Rudolf et al. | May 2021 | A1 |
20210169975 | Rezaei | Jun 2021 | A1 |
20210170029 | Gillespie et al. | Jun 2021 | A1 |
20210205410 | Vitti et al. | Jul 2021 | A1 |
20210236649 | Burian et al. | Aug 2021 | A1 |
20210253692 | Domnowski et al. | Aug 2021 | A1 |
20210260047 | Zarnitsyn et al. | Aug 2021 | A1 |
20210283336 | Bryant et al. | Sep 2021 | A1 |
20210293821 | Dreymann et al. | Sep 2021 | A1 |
20210308217 | Yancopoulos | Oct 2021 | A1 |
20210340605 | Perlee et al. | Nov 2021 | A1 |
20210353713 | Wexler-Cohen et al. | Nov 2021 | A1 |
20210361769 | Kauvar et al. | Nov 2021 | A1 |
20210369616 | Talley | Dec 2021 | A1 |
20210371457 | Casteels et al. | Dec 2021 | A1 |
20210379012 | Corson et al. | Dec 2021 | A1 |
20210393738 | Ke | Dec 2021 | A1 |
20220025032 | Bigelow et al. | Jan 2022 | A1 |
20220031952 | Bryant et al. | Feb 2022 | A1 |
20220054586 | Kim et al. | Feb 2022 | A1 |
20220079876 | Blizzard et al. | Mar 2022 | A1 |
20220087939 | Patel et al. | Mar 2022 | A1 |
20220111015 | Constable et al. | Apr 2022 | A1 |
20220112278 | Li et al. | Apr 2022 | A1 |
20220143137 | Witt et al. | May 2022 | A1 |
20220151920 | Shepard et al. | May 2022 | A1 |
20220162296 | Lin et al. | May 2022 | A1 |
20220175883 | Brockmeyer et al. | Jun 2022 | A1 |
20220226477 | Sloey et al. | Jul 2022 | A1 |
20220227836 | Wang et al. | Jul 2022 | A1 |
20220265740 | Blumenkranz et al. | Aug 2022 | A1 |
20220273764 | Yancopoulos et al. | Sep 2022 | A1 |
20220306732 | Bakhle et al. | Sep 2022 | A1 |
20220331430 | Rosenkranz et al. | Oct 2022 | A1 |
20220356236 | Bigelow et al. | Nov 2022 | A1 |
20230025418 | Wexler-Cohen et al. | Jan 2023 | A1 |
20230063116 | Martin et al. | Mar 2023 | A1 |
20230089914 | Kansara et al. | Mar 2023 | A1 |
20240029897 | Perlee et al. | Jan 2024 | A1 |
20240189402 | Borodic | Jun 2024 | A1 |
Number | Date | Country |
---|---|---|
2981145 | Oct 2016 | CA |
2990582 | Jun 2020 | CA |
102380096 | Apr 2014 | CN |
103816115 | May 2014 | CN |
1767546 | Mar 2012 | EP |
2663325 | Nov 2013 | EP |
3222285 | Sep 2017 | EP |
3452075 | Mar 2019 | EP |
3503883 | Jul 2019 | EP |
3710055 | Sep 2020 | EP |
3713591 | Sep 2020 | EP |
3736574 | Nov 2020 | EP |
3774894 | Feb 2021 | EP |
3785701 | Mar 2021 | EP |
3640643 | Dec 2021 | EP |
3716992 | Aug 2022 | EP |
4070786 | Oct 2022 | EP |
4147709 | Mar 2023 | EP |
4190310 | Jun 2023 | EP |
1997004801 | Feb 1997 | WO |
1998045331 | Oct 1998 | WO |
2000075319 | Dec 2000 | WO |
2002030463 | Apr 2002 | WO |
2002060489 | Aug 2002 | WO |
2003072060 | Sep 2003 | WO |
2004091658 | Oct 2004 | WO |
2005000895 | Jan 2005 | WO |
2006104852 | Oct 2006 | WO |
2006138181 | Dec 2006 | WO |
2007014170 | Feb 2007 | WO |
2007112675 | Oct 2007 | WO |
2007149334 | Dec 2007 | WO |
2009015345 | Jan 2009 | WO |
2010148321 | Dec 2010 | WO |
2011104381 | Sep 2011 | WO |
2011109365 | Sep 2011 | WO |
2011139718 | Nov 2011 | WO |
2012003437 | Jan 2012 | WO |
2012019047 | Feb 2012 | WO |
2012097019 | Jul 2012 | WO |
2013063510 | May 2013 | WO |
2013112438 | Aug 2013 | WO |
2014005728 | Jan 2014 | WO |
2014084508 | Jun 2014 | WO |
2014193821 | Dec 2014 | WO |
2015173260 | Nov 2015 | WO |
2016045626 | Mar 2016 | WO |
2016045627 | Mar 2016 | WO |
2016085750 | Jun 2016 | WO |
2016094673 | Jun 2016 | WO |
2016208989 | Dec 2016 | WO |
2017051273 | Mar 2017 | WO |
17075252 | May 2017 | WO |
2017085253 | May 2017 | WO |
2017087798 | May 2017 | WO |
2017095848 | Jun 2017 | WO |
2017120601 | Jul 2017 | WO |
2017129685 | Aug 2017 | WO |
2018033482 | Feb 2018 | WO |
2018035470 | Feb 2018 | WO |
2018063963 | Apr 2018 | WO |
2018094316 | May 2018 | WO |
2018107005 | Jun 2018 | WO |
2018116198 | Jun 2018 | WO |
2018199408 | Nov 2018 | WO |
2018217995 | Nov 2018 | WO |
2018229034 | Dec 2018 | WO |
2019020777 | Jan 2019 | WO |
2019036619 | Feb 2019 | WO |
2019055902 | Mar 2019 | WO |
2019099921 | May 2019 | WO |
2019099965 | May 2019 | WO |
19108770 | Jun 2019 | WO |
2019124946 | Jun 2019 | WO |
2019173767 | Sep 2019 | WO |
2019199476 | Oct 2019 | WO |
2019214551 | Nov 2019 | WO |
2019217927 | Nov 2019 | WO |
2020008361 | Jan 2020 | WO |
2020055123 | Mar 2020 | WO |
2020087003 | Apr 2020 | WO |
2020103958 | May 2020 | WO |
2020127641 | Jun 2020 | WO |
2020160133 | Aug 2020 | WO |
2020165132 | Aug 2020 | WO |
2020167848 | Aug 2020 | WO |
2020197230 | Oct 2020 | WO |
2020205716 | Oct 2020 | WO |
2020206320 | Oct 2020 | WO |
2020219550 | Oct 2020 | WO |
2020225213 | Nov 2020 | WO |
2020239051 | Dec 2020 | WO |
2021048779 | Mar 2021 | WO |
2021050009 | Mar 2021 | WO |
2021053001 | Mar 2021 | WO |
2021094508 | May 2021 | WO |
2021125852 | Jun 2021 | WO |
2021146328 | Jul 2021 | WO |
2021168218 | Aug 2021 | WO |
2021203769 | Oct 2021 | WO |
2021216916 | Oct 2021 | WO |
21252647 | Dec 2021 | WO |
22008699 | Jan 2022 | WO |
22011323 | Jan 2022 | WO |
22013171 | Jan 2022 | WO |
22026510 | Feb 2022 | WO |
22038038 | Feb 2022 | WO |
2022025660 | Feb 2022 | WO |
22056326 | Mar 2022 | WO |
2022089440 | May 2022 | WO |
2022094340 | May 2022 | WO |
2022101826 | May 2022 | WO |
2022175601 | Aug 2022 | WO |
2022195505 | Sep 2022 | WO |
2022201084 | Sep 2022 | WO |
2022217110 | Oct 2022 | WO |
2022229932 | Nov 2022 | WO |
2022232790 | Nov 2022 | WO |
2022245739 | Nov 2022 | WO |
2023001288 | Jan 2023 | WO |
2023023278 | Feb 2023 | WO |
2023031478 | Mar 2023 | WO |
2023041569 | Mar 2023 | WO |
2023075506 | May 2023 | WO |
Entry |
---|
“Phosphate buffer.” Cold Spring Harbor Protocols, 2006. |
“Guidance for industry Q1A(R2) stability testing of new drug substances and products.” U.S. Department of Health and Human Services Food and Drug Administration, Rockville, MD, Nov. 2003. |
Andersen & Krummen, Recombinant protein expression for therapeutic applications, Current Opinion in Biotechnology, 2002, 13: 117-123. |
Anonymous et al., “Highlights of Prescribing Information,” XP055565606 [retrieved from the Internet:URL:https://web.archive.org/web/20161206164049if_/https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf retrieved on Mar. 7, 2019] (2016). |
AVASTIN label. |
Baynes et al., “Role of arginine in the stabilization of proteins against aggregation,” Biochemistry; vol. 44(12):4919-25. (2005). |
Bontempo, Preformulation Development of Parenteral Biopharmaceuticals, Drugs and the Pharmaceutical Sciences, 1997, 85:91-108. |
Brown et al., Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration, Ophthalmology vol. 118, No. 6, 1098-1097, Jun. 2011. |
Brown et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med. Oct. 5, 2006;355(14):1432-44. |
Brown et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study, Ophthalmology. Jan. 2009;116(1):57-65. |
Brown et al., Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point, Ophthalmology Feb. 2013;120(2):349-54—Epub Nov. 3, 2012. |
Brown 2008—abstract presented at Retina Society 2008. |
Brown 2020—oral presentation at Angiogenesis 2020. |
Cai et al., The efficacy and safety of aflibercept and conbercept in diabetic macular edema, Drug Design, Development and Therapy 2018:12 3471-3483. |
Cao et al., Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration, Invest Ophthalmol Vis Sci. Feb. 1, 2018;59(2):1033-1044. |
CATT Research Group, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med. May 19, 2011;364(20):1897-908—Epub Apr. 28, 2011. |
Chaudhuri et al., High-Throughput Biophysical Analysis of Protein Therapeutics to Examine Interrelationships Between Aggregate Formation and Conformational Stability, The AAPS Journal 16(1): 48-64 (2013). |
Chi et al., Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation, Pharmaceutical Research, Sep. 2003, vol. 20, No. 9, 1325-1336. |
Chong 2009—abstract presented at EU Retina 2009. |
Conbercept product brochure, Angiogenesis, Exudation, and Degeneration 2019 meeting, Miami, Florida (Feb. 9, 2019). |
Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics,” Science Direct, Advanced Drug Delivery Reviews; vol. 58(5-6):686-706. (2006). |
Declaration of Dr. Reiner Gentz in Support of Petition for Inter Partes Review of U.S. Pat. No. 10,464,992, “VEGF Antagonist Formulations Suitable for Intravitreal Administration,” Petition For Inter Partes Review; Chengdu Kanghong Biotechnology Co., Ltd. Exhibit 1003, 76 pages (2021). |
Do et al., Pharmacokinetic Study of Intravitreal Aflibercept in Humans with Neovascular Age-Related Macular Degeneration Retina Apr. 2020;40(4):643-647. |
Do 2007—abstract presented at The International Symposium of Ocular Pharmacology and Therapeutics 2007. |
Drug Vehicle (Code C927), National Cancer Institute (NCI). Retrieved Mar. 8, 2021, from URL:https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C927. |
Engelbert et al., The “Treat and Extend” Dosing Regimen of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration, Opthamology Management, Issue 42, Jun. 2010. |
Eylea, Initial U.S. Approval: 2011, 1-10 (2011). |
Event Brief of Q1 2019 Regeneron Pharmaceuticals Inc Earnings Call—Final FD (Fair Disclosure) Wire, May 7, 2019. |
Event Brief of Q2 2018 Regeneron Pharmaceuticals Inc Earnings Call—Final, FD (Fair Disclosure) Wire, Aug. 2, 2018. |
Event Brief of Q3 2018 Regeneron Pharmaceuticals Inc Earnings Call—Final FD (Fair Disclosure) Wire, Nov. 6, 2018. |
Event Brief of Q4 2018 Regeneron Pharmaceuticals Inc Earnings Call—Final FD (Fair Disclosure) Wire Feb. 6, 2019. |
FDA-1985-D-0033-0003, “Guideline for Submitting Documentation for the Manufacture of and Controls for Drug Products,” 20 pages (Feb. 1987). |
Fraser HM, Wilson H, Rudge JS, Wiegand SJ., Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function.J Clin Endocrinol Metab. Feb. 2005;90(2):1114-22. |
Freeman et al., “High-dose Aflibercept for Eyes with Wet Age-Related Macular Degeneration Resistant to Standard Therapy,” Investigative Ophthalmology & Visual Science; vol. 56 (2015). |
Giannos et al., “Formulation Stabilization and Disaggregation of Bevacizumab Ranibizumab and Aflibercept in Dilute Solutions,” Pharm Res; vol. 35(4):78, 1-15 doi: 10.1007/s11095-018-2368-7 (2018). |
Heier et al., The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing, Ophthalmology. Jun. 2011;118(6):1098-106. |
Heier 2009—oral presentation at The International Symposium of Ocular Pharmacology and Therapeutics 2009. |
HERCEPTIN label. |
Hofmann et al., “Prediction of Protein Aggregation in High Concentration Protein Solutions Utilizing Protein-Protein Interactions Determined by Low Volume Static Light Scattering,” Journal of Pharmaceutical Sciences, vol. 105(6): 1-10. doi: 10.1016/j.xphs.2016.03.022. (2016). |
Holash et al., VEGF-Trap: A VEGF blocker with potent antitumor effects, PNAS, Aug. 20, 2002, vol. 99, No. 17, 11393-11398. |
Holz et al., Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration, Ophthalmology. May 2016;123(5):1080-1089—Epub Feb. 20, 2016. |
Janeway et al., The structure of a typical antibody molecule, Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. |
Kim et al., “Arginine as a protein stabilizer and destabilizer in liquid formulations,” International Journal of Pharmaceutics; vol. 513(1-2):26-37. doi: 10.1016/j.ijpharm.2016.09.003. (2016). |
Kim et al., “Preferential exclusion mechanism by carbohydrates on protein stabilization using thermodynamic evaluation,” International Journal of Biological Macromolecules; vol. 109:311-322. doi: 10.1016/j.ijbiomac.2017.12.089. (2018). |
Kitchens et al., Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials, Ophthalmology, Jul. 2016;123(7):1511-20—Epub Apr. 12, 2016. |
Kitchens 2015—poster presented at The 6th Controversies in Ophthalmology Congress 2015. |
Lu & Sun, Profile of conbercept in the treatment of neovascular age-related macular degeneration, Drug Design, Development and Therapy 9: 2311-2320 (2015). |
LUCENTIS label. |
Lumitin product page (Chinese language including machine translation to English language), available at https://en.cnkh.com/products_information/01-Ophthalmology/Lumitin%C2%AE(Conbercept_Ophthalmic_Solution).pdf, ;last accessed Mar. 8, 2021. |
Magari, “Assessing Shelf Life Using Real-Time and Accelerated Stability Tests,” BioPharm Internatonal, vol. 16, Issue (11):1-12, (Nov. 1, 2003). |
Major et al., Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity, Retina. Jan. 2014;34(1):48-54. |
Mark W. Johnson, MD, Antiangiogenic therapy an advanced treatment for AMD, Ocular Surgery News, Feb. 1, 2006. |
Michael et al., Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye, EMBO Molecular Medicine 6(5): 604-623 (2014). |
Moreno et al., “Study of stability and biophysical characterization of ranibizumab and aflibercept,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 108;156-167; doi: 0.1016/j.ejpb.2016.09.003 (2016). |
Nguyen et al., A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration, Ophthalmology 2009;116:2141-2148. |
Nguyen et al., Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration, J Ocul Pharmacol Ther. Dec. 2012;28(6):581-8. Epub Jul. 9, 2012. |
Nguyen 2007—oral presentation at The Association of Research in Vision and Ophthalmology 2007. |
Nielsen 2020—oral presentation at American Society of Retina Specialists 2020. |
Parkins & Lashmar, The formulation of biopharmaceutical products, Pharmaceutical Science & Technology Today, Apr. 4, 2000, vol. 3, No. 4: 129-137. |
Pieramici & Rabena, Anti-VEGF therapy: comparison of current and future agents, Eye (2008) 22, 1330-1336. |
Press release, Novartis, Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD (Oct. 27, 2018). |
Press Release, Regeneron: Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference, Jan. 7, 2019. |
Press Release, Regeneron: Regeneron Reports First Quarter 2018 Financial and Operating Results, May 3, 2018. |
Press Release, Regeneron: Regeneron Reports Fourth Quarter And Full Year 2018 Financial And Operating Results, Feb. 6, 2019. |
Q1 2019 Regeneron Pharmaceuticals Inc Earnings Call—Final FD (Fair Disclosure) Wire, May 7, 2019. |
Q2 2018 Regeneron Pharmaceuticals Inc Earnings Call—Final, FD (Fair Disclosure) Wire, Aug. 2, 2018. |
Q3 2018 Regeneron Pharmaceuticals Inc Earnings Call—Final FD (Fair Disclosure) Wire, Nov. 6, 2018. |
Q4 2018 Regeneron Pharmaceuticals Inc Earnings Call—Final FD (Fair Disclosure) Wire, Feb. 6, 2019. |
Ohr et al., “Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration,” informa healthcare, ISSN 1465-6566 pp. 1-7, (2012). [Expert Opin. Pharmacother. Downloaded from informahealthcare.com by IBI Circulation—Ashley Publications Ltd on Feb. 13, 2012]. |
Randolph & Jones, Surfactant-Protein Interactions, Rational Design of Stable Protein Formulations, 2002, pp. 159-175, Springer, Boston, MA. |
RAPTIVA label. |
Regeneron Annual Report 2018. |
Regeneron Corporate Presentation, Mar. 2019. |
Regeneron Gets A Win With Eylea Approval In Diabetic Retinopathy Scrip Intelligence, May 13, 2019. |
Regeneron Pharmaceuticals Inc at J.P. Morgan 2019 Spring Biotech Conference Call—Final FD (Fair Disclosure) Wire, Mar. 15, 2019. |
Regeneron Pharmaceuticals Inc at Morgan Stanley Healthcare Conference—Final FD (Fair Disclosure) Wire, Sep. 12, 2018. |
Regeneron Pharmaceuticals Outlines Pipeline Progress, Shares 2019 Financial Guidance MT Newswires Live Briefs, Jan. 7, 2019. |
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference PR Newswire, Jan. 7, 2019. |
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference Plus Company Updates (PCU), Jan. 8, 2019. |
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results PR Newswire, Feb. 6, 2019. |
Regeneron's Eylea hits double-digit growth for 2018, and it's ‘far from done,’ CEO says Indian Pharma Industry: Policies, Dec. 27, 2018. |
Regeneron's Eylea hits double-digit growth for 2018, and it's ‘far from done,’ CEO says FiercePharma Marketing, Jan. 9, 2019. |
RegenBase Knowledge Base, “Controls in SCI experiments,” Chengdu Kanghong Biotechnology Co., Ltd. Exhibit 1034, 2 pages (Retrieved Jan. 6, 2021 from http://regenbase.org/control-groups.html). |
REMICADE label. |
Rosenfeld et al., Ranibizumab for neovascular age-related macular degeneration,N Engl J Med. Oct. 5, 2006;355(14):1419-31. |
Rudge et al., VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene®-based Discovery of the Next Generation of Angiogenesis Targets, Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70: 411-418. |
SA Transcripts, “Regeneron Pharmaceuticals (REGN) Q3 2018 Results—Earnings Call Transcript,” Seeking Alpha: 1-27, (Nov. 6, 2018). [https://seekingalpha.com/article/4219037-regenerone-pharmaceuticals-regn-q3-2018-results-earnings-call-transcript?part=single]. |
Sawada et al., Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration, Clinical and Experimental Ophthalmology (2017) 46:46-53. |
Schleifer et al., “REGENERON Science to Medince,” JP Morgan 2019, 1-29; Jan. 7, 2019. |
Schelifer & Yancoupolos, JP Morgan Presentation Jan. 7, 2019. |
SEC Form 10-K, Regeneron, Dec. 31, 2018. |
SEC Form 10-Q, Regeneron, Mar. 31, 2019. |
SEC Form 8-K, Regeneron, Jan. 7, 2019. |
SIMULECT label. |
Shire et al., “Formulation of proteins and monoclonal antibodies mAbs,” Monoclonal Antibodies: Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product, p. 93-120, XP009192951 (2015). |
Stacker et al., A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors, Journal of Visualized Experiments, J. Vis. Exp. (109), e53867 (2016). |
Stewart, “Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug,” Department of Ophthalmology, Mayo Clinic Florida, vol. 10:497-508, (2011). XP009172512. |
Stewart & Rosenfeld, Predicted biological activity of intravitreal VEGF Trap, Br J Ophthalmol May 2008;92(5):667-668—Epub Mar. 20, 2008. |
Stewart, Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities, Pharmaceutics 2018, 10, 21. |
United States: Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference Tenders Info, Jan. 12, 2019. |
U.S. Appl. No. 16/409,631, Requirement for Restriction/Election dated Sep. 24, 2020. |
U.S. Appl. No. 16/409,631, Non-Final Office Action dated Jan. 25, 2021. |
U.S. Appl. No. 16/409,631, Notice of Allowance dated Jun. 17, 2021. |
Wang, Advanced protein formulations, Protein Science 24:1031-1039 (2015). |
Wang-Gillam et al., A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors, Invest New Drugs (2012) 30:1958-1961. |
WIPO Application No. PCT/US2019/031879, PCT International Search Report and Written Opinion of the International Searching Authority dated Sep. 25, 2019. |
Whitaker et al., “A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities,” Journal of Pharmaceutical Sciences; Nov;106(11):3230-3241. doi: 10.1016/j.xphs.2017.06.017. (2017). |
Wulff et al., Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap RIR2, Endocrinology, Jul. 2002, 143(7): 2797-2807. |
Wykoff et al., SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results, Ophthalmic Surg Lasers Imaging Retina. Mar.-Apr. 2013;44(2):121-6. |
Wykoff et al., Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD, Ophthalmology Sep. 2013;120(9):1945-6. |
XOLAIR label. |
You et al., High-Dose High-Frequency Aflibercept For Recalcitrant Neovascular Age-Related Macular Degeneration, Retina: Jun. 2018—38(6): 1156-1165. |
Zaltrap, “Injection for Intravenous Infusion Prescribing Information,” Prescribing Information; 1-20, (2012). [http://products.sanofi.us/Zaltrap/Zaltrap.html]. |
Ziemssen et al., Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues, Expert Opin Drug Saf . Jan. 2016;15(1):75-87—Epub Dec. 11, 2015. |
Chang et al., “Ziv-Aflibercept as a Possible Alternative to Aflibercept,” Medical Retina, Retina Today, pp. 67-68, (2014). |
Naoto et al., “Arginine and lysine reduce the high viscosity of serum albumin solutions for pharmaceutical injection,” Journal of bioscience and bioengineering, vol. 117 (No. 5): 539-543, (2013). [http://hdl.handle.net/2241/00121920], [doi: 10.1016/j.jbiosc.2013.10.016]. |
Coors et al., “Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions,” Ann Allergy Asthma Immunol, vol. 95: 593-599, (2005). |
Ema et al., “Evaluation of Developmentl neurotoxicity of polysorbate 80 in rats,” Science Direct, Reproductive Toxicology, vol. 25: 89-99, (2008). [DOI: 10.1016/j.reprotox.2007.08.003]. |
Gajdova et al., “Delayed Effects of neonatal exposure to tween 80 on female reproductive organs in rats,” Fd Chem.Toxic, vol. 31 No. 3: 183-190, (1993). |
Thackaberry et al., “Comprehensive Investigation of Hydroxypropyl Methylcellulose, Propylene Glycol, Polysorbate 80, and Hydroxypropyl-Beta-Cyclodextrin for use in General Toxicology Studies,” Toxicological Sciences, vol. 117 No. 2: 485-492, (2010). [Downloaded from https://academic.oup.com/toxsci/article/117/2/485/1641380 by Williams Connolly user on Dec. 17, 2021]. |
Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532-536. |
Framme C, Eter N, Hamacher T, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: Twelve month outcomes of PERSEUS. Ophthalmology Retina. 2018;2:539-549. |
Khurana RN, Rahimy E, Joseph WA, et al. Extended (every 12 weeks or longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of VIEW trials. Am J Ophthalmol. 2019;200:161-168. |
Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682-686. |
Avery, “What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?,” Open Access, Br J Ophthalmol, vol. 98 i7-i10, (2014). [doi:10.1136/bjophthalmol-2013-303844]. |
Hanna et al., “Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension,” Clinical Kidney Journal, 2019, vol. 12, No. 1, 92-100. [doi: 10.1093/ckj/sfy060]. |
Hayman et al., “VEGF Inhibition, Hypertension, and Renal Toxicity,” Curr Oncol Rep. Aug. 2012 ; 14(4): 285-294. [doi:10.1007/s11912-012-0242-z]. |
Raiser et al., “The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension,” Macmillan Publishers Limited, Eye (2009) 23, 1714-1718. [doi:10.1038/eye.2008.360; published online Dec. 12, 2008]. |
Anonymous, Meeting Archive Titled “PA003 Eighteen-Month Results From an Extension Study of a Phase 2, Dose- and Interval-Ranging Study of VEGF Trap-Eye in Wet AMD,” presented by David S Boyer, MD at Moscone Center (Oct. 2009). |
Anonymous, Meeting Archive Titled “PA080 One-Year Results of a Phase 2 Study of Intravitreal VEGF Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration,” presented by David S Boyer, MD at Georgia World Congress Center (Nov. 2008). |
Anonymous, Meeting Archive Titled “PO259 OCT and Fluorescein Angiography Outcomes Through 1 Year for a Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular AMD,” presented by Peter K Kaiser, MD at Moscone Center (Oct. 2009). |
Anonymous, Meeting Archive Titled “PO260 VEGF Trap-Eye Vision-Specific Quality of Life Through 52 Weeks in Patients with Neovascular AMD in CLEAR-IT 2: A Phase 2 Clinical Trial,” presented by Allen C Ho, MD at Moscone Center (Oct. 2009). |
Anonymous, Meeting Archive Titled “PO571 OCT and Fluorescein Angiographic Outcomes Through 1 Year for the Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular AMD,” presented by Quan Dong Nguyen, MD at Georgia World Congress Center (Nov. 2008). |
Benz et al., “CLEAR-IT-2: Interim Results Of The Phase II, Randomized, Controlled Dose-and Interval-ranging Study Of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age-related Macular Degeneration (AMD),” ARVO Annual Meeting Abstract (May 2007). |
Brown, “High-Dose Aflibercept—Rationale & Clinical Studies” Houston, TX Feb. 9, 2020. |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 01 (Apr. 28, 2006). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 02 (Oct. 3, 2006). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 03 (Jul. 25, 2007). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 04 (Jan. 23, 2009). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 05 (Apr. 29, 2009). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 06 (Jan. 26, 2010). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 07 (Jan. 25, 2011). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 08 (Jun. 8, 2011). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320775, “Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,” Version 09 (Mar. 16, 2015). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 01 (Apr. 28, 2006). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 02 (Aug. 1, 2006). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 03 (Oct. 3, 2006). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 04 (Jul. 24, 2007). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 05 (Jan. 23, 2009). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 06 (Apr. 28, 2009). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 07 (Nov. 30, 2010). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 08 (Apr. 20, 2011). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 09 (Dec. 1, 2011). |
ClinicalTrials.gov Archive, History of Changes for Study: NCT00320788, “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),” Version 10 (Jan. 27, 2012). |
Do et al., “Results of a Phase 1 Study of Intravitreal VEGF Trap in Subjects with Diabetic Macular Edema: The CLEAR-IT DME Study,” ARVO Annual Meeting Abstract (May 2007). |
Do et al., “VEGF Trap-Eye Vision-specific Quality of Life through 52 Weeks in Patients with Neovascular AMD in CLEAR-IT 2: A Phase 2 Clinical Trial,” ARVO Annual Meeting Abstract (Apr. 2009). |
Eylea, “Wet AMD: Dosing Flexibility,” https://hcp.eylea.us/about/wet-amd-dosing/ (accessed Jan. 5, 2022). |
Eylea Label (revised Mar. 2021), https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125387s069lbl.pdf (accessed Sep. 26, 2022). |
Eylea Label (revised May 2019). |
Eylea Label (revised Nov. 2011), https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf (accessed Apr. 4, 2023). |
Eylea Label (revised Oct. 2014), https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s043lbl.pdf (accessed Sep. 26, 2022). |
Eylea Label (revised Sep. 2012), https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf (accessed Sep. 26, 2022). |
Eylea Label (revised Feb. 2023), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s075lbl.pdf (accessed Apr. 4, 2023). |
Eylea Label (revised May 2016), https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125387s051lbl.pdf (accessed Sep. 26, 2022). |
Eylea Label (revised Aug. 2018). |
Heier et al., “CLEAR-IT 2: Phase 2, Randomized Controlled Dose and Interval-Ranging Study of Intravitreal VEFG Trap Eye in Patients with Neovascular Age-Related Macular Degeneration: Predictive Factors for Visual Acuity,” ARVO Annual Meeting Abstract (Apr. 2009). |
Heier et al., “The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing,” Ophthalmology 118(6):1098-1106 (Jun. 2011). |
Heier et al., “The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing: Erratum,” Ophthalmology, 118(9):1700 (Sep. 2011). |
“High Dose Aflibercept Phase 2 Study in Patients with neovascular AMD” Candela, Feb. 12, 2022. |
Ho et al., Slides entitled “VEGF Trap-Eye in Wet AMD-CLEAR IT 2: One-Year Key Results,” Retina Society, pp. 1-35 (2008). |
Ho, Slides entitled “VEGF Trap-Eye in Wet AMD-CLEAR-IT 2: One-Year OCT and FA Outcomes,” CLEAR-IT 2 Study Group, pp. 1-24 (Sep. 28, 2008). |
Nguyen et al., “Results of a Phase I, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreous VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration,” ARVO Annual Meeting Abstract (May 1, 2006). |
Paul et al., “Direct analysis of mAb aggregates in mammalian cell culture supernatant,” BMC Biotechnology, vol. 14:99 (2014); 11 pages. |
Regeneron Pharmaceuiticals, Inc. press release, “Eylea (Aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients With Diabetic Retinopathy,” Feb. 8, 2020. |
Regeneron Pharmaceuticals, Inc. press release, “Regeneron announces encouraging topline phase 2 data of high-dose aflibercept in wet age-related macular degeneration,” Tarrytown, New York. Aug. 24, 2021. |
Regeneron Pharmaceuticals, Inc., “VEGF Trap-Eye CLEAR-IT 2 Final Primary Endpoint Results,” presented at the 2007 Retina Society Conference in Boston, Massachusetts (Sep. 30, 2007). |
Regeneron Pharmaceuticals, Inc., “EYLEA,” https://eylea.us/ (accessed May 18, 2022). |
Regeneron Pharmaceuticals, Inc., “CLEAR-IT-2: Interim Results Of The Phase II, Randomized, Controlled Dose-and Interval-ranging Study Of Repeated Intravitreal VEGF Trap Administration In Patients With Neovascular Age-related Macular Degeneration (AMD),” poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007). |
Regeneron Pharmaceuticals, Inc., “Optical Coherence Tomography Outcomes of a Phase 1, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration: The CLEAR-IT 1 Study,” poster presented at the 2007 Association for Research in Vision and Ophthalmology meeting in Ft. Lauderdale, Florida (May 2007). |
Slakter et al., “Influence of Baseline Angiographic Classification on Outcomes in the CLEAR-IT 2 Phase 2 Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration,” ARVO Annual Meeting Abstract (Apr. 2010. |
Slides for the 2008 Retina Society Meeting “VEGF Trap-Eye in Wet AMD CLEAR-IT 2: Summary of One-Year Key Results,” Sep. 28, 2008. |
Tolentino et al., “One-year Results Of The Da Vinci Study of VEGF Trap-Eye In DME,” ARVO Annual Meeting Abstract, Investigative Ophthalmology & Visual Science, 52:6646 (Apr. 2011). |
Bakri et al., “Pharmacokinetics of Intravitreal Ranibizumab (Lucentics),” American Academy of Ophthamology, vol. 114, No. 12: 2179-2182, (2007). [doi:10.1016/j.ophtha.2007.09.012]. |
Choi et al., “Normative Data of Ocular Biometry Optical Coherence Tomography, and Electrophysiology Conducted for Cynomolgus Macaque Monkeys,” Translation Vision Science & Technology, vol. 10 (No. 13) Article 14: 1-11, (2021). [Retrieved from the Internet Oct. 4, 2023: https://doi:org/10.1167/tvst.10.13.14]. |
AusPAR Eylea Afilbercept Bayer Australia Ltd., PM-2010-03802-3-5 Final; Jul. 30, 2012, pp. 1-24. |
Eylea Assesment report; Committee for Medicinal Products for Human Products for Human Use (CHMP), European Medicines Agency; EMA/646256/2012 corr; Sep. 20, 2012, 1-83 pages. |
History of Changes for Study: NCT00383370, “To Access the Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap in Subjects With Wet AMD,” ClinicalTrails.gov archive, 1-33 pages; Apr. 20, 2011. |
“Zhang et al.,” A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Releated Macular Degeneration, American Academy of Ophthamology, pp. 672-678, (2011). [doi:10.1016/j.ophtha.2010.08.008; ISSN 0161-6420/11/$]. |
Regeneron Pharmaceuticals, Inc., “Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Releated Macular Degeneration (AMD),” ClinicalTrials.gov ID NCT00320788, Mar. 1, 2012. [https://www.clinicaltrials.gov/study/NCT00320788?term=NC00320788&rank=1]. |
Arevalo et al., Retinal Detachment after Bevacizumab, Ophthalmology 18(11):2304.e3 (Nov. 2011). |
Australian Public Assessment Report for Afibercept, Australian Government, Department of Health & Aging, Therapeutic Goods Administration, Jul. 2012. |
Avastin label (revised Jan. 2021). |
Boulanger-Scemama E, Querques G, About F, et al. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real life setting. J Fr Opthalmol 2015; 38(7): 620-7. |
Bressler et al., NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol, LM, Malia M, Wells JA 3rd, for the Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening Following Intravitreaous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Opthamol. Mar. 1, 2018;136(3):257-269 &Erratum in:JAMA Opthamol. May 1, 2018;136(5):601. |
Brown et al., Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration, Opthalmology, 2011;118:1089-1097 (2011). |
Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal afilbercept for diabetic macular edema, 100-week results from the VISTA and VIVID studies. Opthalmology, 2015;122(10): 2024-52. |
Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Opthalmology 2013; 120(5):1046-56. |
Center For Drug Evaluation and Research Application Number: 125418orig1s000, Clinical Pharmocology And Biopharmaceutics Review(s), Feb. 2012. |
Center For Drug Evaluation and Research, FDA, Approval Pacakge for Application No. 125387Orig1s048, Eylea, Mar. 25, 2015. |
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevelance for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-81. |
Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Opthalmol Retina 2018; 2(12): 1179-87. |
Da Vinci, clinicaltraisl.gov posting NCT00789477, latest version, Aug. 28, 2014. |
Do DV, Nguyen QD, Boyer D, Schmidy-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS; da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Opthalmology. Aug. 2012;119(8):1658-65-Epub Apr. 24, 2012. |
Do et al., Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). Eye (Lond). Dec. 2015;29(12):1538-44. |
Dugel et al., Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Mascular Degeneration: A Randomized Trial. Opthalmology. Sep. 2017;124(9):1296-1304-Epub May 24, 2017. |
Ehlken C, Helms M, Bohringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Opthalmol 2018; 12: 13-20. |
EU Clinical Trials Register, EudraCT No. 2007-00583-25, UK, Dec. 7, 2007. |
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), EMA/430291/2014, Assessment Report, Eylea, Jun. 26, 2014. |
Heir JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Opthalmology 2012; 119(12): 2537-48. |
Herceptin label (revised Feb. 2021). |
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Opthalmology 2014; 121(11):2181-92. |
Jaffe GJ, Toth CA, Macular Morphology and Visual Acuity in Year Five of the Comparision of Age-related Macular Degeneration Treatments Trials. Opthalmology 2019- Epub Sep. 3, 2018; 126(2): 252-60. |
Kim JH. Re: Nguyen et al.: Characterization of poor visual outcomes of neovascular age-related macular degeneraton treated with anti-vascular endothelial growth factor agents (Opthalmology. 2019;126:735-742). Opthalmology. Apr. 2020;127(4):e21. |
Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Opthalmology 2014; 121(11): 2247-54. |
Lally DR, Shah CP, Heier JS. Vascular endothelial growth factor and diabetic macular edema. Surv Opthalmolo 2016; 61(6): 759-68. |
Lanzetta P, Loewenstein A; Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Grafes Arch Clin Exp Opthalmol. Jul 2017;255(7)1259-1273-Epub May 19, 2017. |
Lucentis label (revised Mar. 2018). |
Liang, Fang, “Cataloguing In Publication (CI P) Data,”Pharmaceutics/Editor-in-Chief Fang Liang.—Third Edition—Beijing: China Medical Science Press, Mar. 2016. [ISBN 978-7-5067-7405-5; www.cmstp.com]. |
Mitchell, P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet (London, England) 2018; 392(10153): 1147-59. |
Modarres et al., Intravitreal Injection of 2.5 mg versus 1.25 mg Bevacizumab (Avastin) for Treatment of CNV Associated with AMD, Retina 29:319-324, 2009. |
Nguyen CL, Gillies MC, Nguyen V, et al. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents. Opthalmology 2019- Epub Dec. 6, 2018; 126(5): 735-42. |
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Opthalmology 2012; 119(4): 789-801. |
Papadopulos N, Martin J, Ruan Q, Rafique A, Rosconi, MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. Jun. 2012;15(2):171-85. |
Raptiva label (revised Mar. 2009). |
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results, Plus Company Updates(PCU), Feb. 7, 2019. |
Remicade label (Revised May 2020). |
Regula JT, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases, EMBO Mol Med. 2016;8(11):1265-1288. |
Schmidt-Erfuth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Opthalmology 2014;121(1): 193-201. |
Semeraro F, Morescalchi F, Duse S, Parmaggiani F, Gambicorti E, Costagliola C. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther 2013; 7: 711-22. |
Simulect label (revised Aug. 2020). |
Weiss M, Sim DA, Herold T, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 2018; 38(12):2293-300. |
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2(2):e106-16. |
Xolair label (revised Dec. 2020). |
clinicaltrials.gov posting NCT00090623, A Study of rhuFav V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD), Pier, Jun. 21, 2013. |
clinicaltrials.gov posting NCT01217944, Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia, Radiance, Jun. 21, 2013. |
clinicaltrials.gov posting NCT00485836, A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (Cruise), Jul. 28, 2017. |
clinicaltrials.gov posting NCT00486018, A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (Bravo), May 10, 2017. |
clinicaltrials.gov posting NCT00056836, A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occulut Subfoveal Neovascular Macular Degeneration, Marina, May 16, 2014. |
clinicaltrials.gov posting NCT00061594, A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration, Anchor, Mar. 19, 2014. |
clinicaltrials.gov posting NCT00473382, A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (Ride), Apr. 17, 2017. |
clinicaltrials.gov posting NCT00473330, A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (Rise), Apr. 17, 2017. |
clinicaltrials.gov posting NCT02434328, Efficacy and Safety of RTH258 Versus Aflibercept—Study 2, Harrier, Mar. 28, 2018. |
clinicaltrials.gov posting NCT02307682, Efficacy and Safety of RTH258 Versus Aflibercept—Study 1, Hawk, May 28, 2018. |
clinicaltrials.gov posting NCT00891735, A Study of Ranibizumab Administed Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (Harbor), Jan. 18, 2013. |
clinicaltrials.gov posting NCT00036946, VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma, REGENERON-VGFT-SR-0103, Jun. 3, 2016. |
clinicaltrials.gov posting NCT00527423, Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD, Jun. 12, 2013. |
clinicaltrials.gov posting NCT00383370, Safety and Tolerability of Intravitreal VEGF Trap Formulatuons in Subjects With Neovacular AMD, VGFT-OD-0603, Apr. 21, 2011. |
clinicaltrials.gov posting NCT00320775, Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD, CLEAR-UT1, Mar. 18, 2015. |
clinicaltrials.gov posting NCT00789477, DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYELA®; BAY86-5321)] INverstigation of Clinical Impact, Da Vinci, Sep. 9, 2014. |
clinicaltrials.gov posting NCT00320788, Safety and Efficacy of Repeated Intravitreal Administation of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Weg Age-Related Macular Degeneration (AMD), CLEAR-IT2, Mar. 1, 2012. |
clinicaltrials.gov posting—NCT002305238—Nov. 28, 2014 to Dec. 20, 2018, Dec. 20, 2018. |
clinicaltrials.gov posting—NCT002581891—Oct. 20, 2015 to May 12, 2020, May 12, 2018. |
clinicaltrials.gov posting NCT00036946, Jun. 1, 2016. |
clinicaltrials.gov posting NCT00527423, Jun. 10, 2013. |
clinicaltrials.gov posting NCT01331681, Mar. 20, 2016. |
Gaudreault et al., “Pharmacokinketics and Retinal Distribution of Ranibizumab, A Humanized Antibody Fragment Directed Against VEGAF-A, Following Intravitreal Administration in Rabbits,” Retina, The Journal of Retinal and Vitreous Diseases, vol. 27 (No. 9): 1260-1266, (2007). |
Gaudreault et al., “Preclinical Pharmacokinketics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration,” Publication, vol. 46 (No. 2): 726-733, (2005). [dowloaded from lovs.arvojournals.org on Oct. 3, 2023]. |
Assessment report; International non-propriatary name; faricimab; Procedure No. EMEA/H/C/005624/0000. Committee for Medicinal Products for Human Use (CHMP) 319 pages (Jul. 21, 2022). [EMA/68744/2022]. |
U.S. Appl. No. 18/367,444, Non-Final Office Action mailed May 21, 2024. |
Anonymous: “Product information EYLA aflibercept (rch)”, Apr. 15, 2015 (Apr. 15, 2015) XO093174268, [Retreived from the Internet: URL:https://www.tga.gov.au/sites/default/f iles/auspar-aflibercept-150721-pi-pdf]. |
Australian Public Assesment Report for Aflibercept, Australian Government, Department of Health & Aging, Therapeutic Goods Administration, Proprietary Product Name: Eylea sponsored by Bayer Australia Ltd (publication date Jul. 21, 2015). |
Clinical Trials for “Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema,” sponsored by Regeneron Pharmaceuticals, NCT00320814 (publication date Jun. 10, 2011). |
Avastin label (revised Dec. 2017). |
Herceptin label (Sep. 1998). |
Lucentis label (revised Oct. 2014). |
Remicade label (revised Nov. 2013). |
Simulect label (May 1998). |
Xolair label (2003). |
Borwankar et al., “Viscosity Reduction of a Concentrated Monoclonal Antibody with Arginine:HCI and Arginine·Glutamate,” I&EC Research, American Chemical Sociaet, vol. (No. 55): 11225-11234, (2016). [DOI: 10.1021/acs.iecr.6b02042]. |
Number | Date | Country | |
---|---|---|---|
20210353714 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
62813882 | Mar 2019 | US | |
62769876 | Nov 2018 | US | |
62752127 | Oct 2018 | US | |
62669506 | May 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16409631 | May 2019 | US |
Child | 17384070 | US |